Trading Analysis Report: TEAM¶

Analysis date: 2026-10-21
Rating: Underweight
Generated: 2026-10-21 12:22:55
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 226.83 Price As Of: 2026-10-21

(TEAM, Atlassian Corporation, NMS-listed. The tools don't label the currency, but it should be USD.)

TEAM: Technical Analysis Report (as of 2026-10-21)¶

1. Data-integrity notes¶

The 2026-10-21 bar may be incomplete. Its volume is 1,431,294, the lowest in the recent run apart from the holiday-thin 2025-12-24 and 2025-12-26 sessions. If this is a partial-session print, the close, RSI, Bollinger position, ADX and OBV could all shift by the final close. RSI at 70.03 sits right on its threshold, so it is especially sensitive.
No conflicts found between the snapshot and the indicator tools. RSI (70.03), MACD (10.54) and ATR (9.24) match. The daily z-score of 1.88 also matches what the snapshot's Bollinger values imply: (226.83 − 199.84) / ((228.60 − 199.84) / 2) ≈ 1.88.
Source of the moving averages and bands. The 10 EMA, 50 SMA, 200 SMA, Bollinger bands, MACD signal and histogram come from the verified snapshot. I did not request them separately.
Not available from my tools: news, earnings calendar and fundamentals. Anything I say about catalysts is inference and is labelled as such.

2. Indicators chosen and why¶

The stock went from a 67% drawdown to a roughly 4x rally and is now at a 12-month high, so I covered each category with one or two indicators:

Category	Indicator	Reason
Trend (multi-timeframe)	`supertrend`	Gives direction and trailing stops on weekly, monthly and daily bars. Also gives stop distances for risk sizing.
Trend strength	`adx`	Separates a real trend from chop. ADX moved from about 10 to about 42 in three weeks.
Momentum	`rsi`, `macd`	RSI is at the overbought threshold. MACD checks whether momentum confirms the new price high.
Volatility	`atr`	Stock-specific volatility, used for stop and position sizing.
Volume	`obv`	Tests whether the breakout has participation behind it.
Exhaustion	`td_9`	A daily completed 9 is flagged. I want to see how the weekly and monthly counts compare.
Stretch	`z_score`	Measures how far price is from its mean on three timeframes.

I did not pull +DI/−DI. ADX direction is inferred from price, not confirmed by a DI cross.

3. Price context (252 sessions, 2025-10-21 to 2026-10-21)¶

Decline: Close of 176.08 on 2025-11-03, then a slide to a closing low of 57.15 on 2026-04-10 (intraday low 56.01), about −67.5%. Selling accelerated in January and February on rising volume. Examples are 8.30M on 2026-01-16 and 14.0M on 2026-02-06.
Recovery in three event-style legs:
2026-05-01: gap from 68.59 to 88.88 (about +29.6%) on 27.4M shares.
2026-05-29 to 2026-06-01: 93.29 to 115.95.
2026-08-07: gap from 110.17 to 149.07 (about +35.3%) on 20.1M shares.
These are the largest-volume sessions of the recovery. They look event-driven, possibly earnings, but I can't confirm that from the data I have.
September digestion: Closes ranged from 175.96 (09-29) to 195.67 (09-21) after the 08-31 close of 194.17.
October breakout: The first close above the September range was 196.65 on 10-05, and the breakout was decisive at 203.57 on 10-08. Since 09-30 (179.29) the stock is up about 26.5% in 15 sessions.
Today's bar: The close of 226.83 and the high of 227.36 are the highest in the 252-row dataset. The close sits at about 93% of the day's range (219.76 to 227.36).
Overall: The stock is about 297% above its April closing low and about 28.8% above its November 2025 closing high of 176.08.

4. Trend structure¶

Moving averages (snapshot)

Average	Value	Close vs. average
10 EMA	212.13	+6.9%
50 SMA	188.14	+20.6%
200 SMA	115.40	+96.6%

The stack is fully bullish: price > 10 EMA > 50 SMA > 200 SMA.
The 200 SMA is still catching up to the V-shaped recovery. It confirms the regime but offers no nearby reference.
The 50 SMA being far above the 200 SMA is consistent with a golden-cross regime. I can't date the cross from this data.

SuperTrend (14, 3x ATR)

Timeframe	Direction	Stop	Close above stop
Weekly (primary)	UP	160.05	+41.73%
Monthly	UP	75.43	+200.75%
Daily	UP	195.85	+15.83%

All three tiers agree, so there is no timeframe conflict.
The daily stop of 195.85 is about 3.35 ATR below the close. It sits near the top of the September closing range (195.67 on 09-21).
The weekly stop of 160.05 is about 7.2 ATR below the close and below the whole September range.

ADX: 41.74

ADX was 10.22 on 10-02, then rose every session to 41.74 today.
Earlier, ADX was 38.89 on 09-21. It fell to the 10-02 low as the stock consolidated.
A reading above 40 means a strong, mature trend. A rising ADX means the trend is still strengthening.
Because I did not pull +DI/−DI, the "up" direction comes from price and SuperTrend, not from a DI cross.

5. Momentum¶

RSI: 70.03

This is the highest reading in the 30-day window, up from 47.73 on 09-29.
RSI touched 69.91 on 10-15, then fell to 60.84 on 10-16 as price reversed, and has since climbed back.
RSI is making a higher high alongside a higher price high (67.73 on 09-21 vs. 70.03 now), so there is no RSI divergence.
In strong trends RSI can stay above 70 for extended periods. It is a warning of stretched momentum, not a reversal signal on its own.

MACD: 10.54 vs. signal 8.87, histogram +1.68

The MACD line has stayed positive throughout the 30-day window.
It troughed at 5.15 on 10-02 and has risen to 10.54. It rose on each of the last three sessions: 9.05, 9.69, 10.54.
Momentum is positive and expanding on the short term.
Caveat on divergence: Price is above its 09-21 level (195.67), but the MACD line (10.54) is still below its 09-21 reading (11.96). That is a mild possible bearish divergence within this 30-day window. It is unconfirmed while the line and histogram are still rising. It would matter more if MACD rolls over while price keeps making highs.

6. Volatility and risk geometry¶

Bollinger bands (snapshot)

Band	Value
Upper	228.60
Middle	199.84
Lower	171.08

The close is 1.77 below the upper band, so %B is about 0.97. Today's high of 227.36 did not reach the band.
Price is 13.5% above the middle band.
The upper band can be "walked" during strong trends. A close above it would be a continuation sign, not a reversal signal by itself.

ATR: 9.24, about 4.1% of price

ATR has been steady in a 8.34 to 9.64 range over the last 30 days, so recent realized volatility is stable but high.
The distances from the close to the reference levels, in ATR terms:

Level	Value	Distance from close
10 EMA	212.13	14.70 (about 1.6 ATR)
Daily SuperTrend stop	195.85	30.98 (about 3.35 ATR)
Weekly SuperTrend stop	160.05	66.78 (about 7.2 ATR)
1 ATR below close	217.60	9.24
2 ATR below close	208.35	18.48

The stock has absorbed sharp pullbacks inside this uptrend. For example, it fell from 96.43 (07-20) to 80.15 (07-23), about −17%, in three sessions.
The 10-16 reversal bar: It opened at 218.95, made a high of 223.7 and a low of 204.0, and closed at 207.82, down from 217.12 (about −4.3%). Price recovered to new highs within three sessions. That reversal bar shows how quickly sentiment can swing at this level.

7. Volume (OBV)¶

OBV is −71.46M. That is its highest reading in the 60-day window, above the prior high of −73.22M on 09-17. It rose from −91.31M on 09-29.
Price and OBV are both at window highs, so volume confirms the move and there is no OBV divergence. The absolute level is not meaningful, so the slope is what matters.
Nuance: The October advance came on modest volume, roughly 1.4M to 3.7M a day. That is much lighter than the 20M+ sessions that drove earlier legs. The advance is confirmed by direction, but participation is not heavy.
Today's OBV increment is based on the possibly partial volume of 1.43M.

8. Exhaustion and stretch¶

TD Sequential (sell-setup counts, which are the up-trend exhaustion counts)

Timeframe	Count	Meaning
Weekly (Tier 1)	−3 of 9	Early
Monthly (Tier 2)	−5 of 9	Mid-stage
Daily (Tier 3)	−9 of 9	Complete, reversal watch

Higher tiers carry more weight. The daily 9 is a short-term exhaustion flag. The weekly and monthly counts are far from completion, which suggests the larger up-move is not yet exhausted on those timeframes.
The daily 9 may not be fresh. In my own check of the closes, every session from 10-01 to 10-21 (15 sessions) closed above the close four sessions earlier. The 10-16 comparison passed by only 0.07 (207.82 vs. 207.75). On that basis the ninth bar was around 10-13 (close 208.04), and the tool appears to hold the count at 9. Price has since risen about 9% to 226.83. I can't confirm the tool's counting convention, so treat this as an observation, not a verified fact. A completed 9 has not stopped the advance so far.

Z-score (20-period)

Timeframe	Reading
Weekly (primary)	+1.50
Monthly	+1.33
Daily	+1.88

Nothing has reached the |z| ≥ 2 stretch threshold. The daily reading is close to it.
The weekly and monthly readings are moderate, so stretch is concentrated in the short term.

9. Synthesis¶

Where the evidence agrees (bullish) - All three SuperTrend tiers are up, and the MA stack is aligned. - ADX is above 40 and rising. - MACD is above its signal with a positive histogram. - OBV is at a 60-day high, in step with price. - The stock is at a 12-month high.

Where the evidence warns (short-term stretch) - RSI is at exactly 70.03, and the close is about 0.8% below the upper Bollinger band. - The daily z-score is 1.88, and the daily TD count is at 9. - The MACD line is below its 09-21 level despite higher prices. - Volume on the advance is light. - The close is about 6.9% above the 10 EMA.

Weighting by timeframe: The primary weekly signals (SuperTrend up, TD at −3, z-score at +1.50) are healthy. The stretch signals are mostly on the daily timeframe. The data fits a strong trend with short-term overextension. It does not show a trend breakdown.

Scenarios to watch (conditional, not predictions) 1. Continuation: Closes above the 228.60 upper band, with ADX still rising, the MACD histogram expanding and OBV making new highs. Strong trends can ride the band and hold RSI above 70. 2. Consolidation or pullback: Stretch plus the daily TD 9 makes a pause plausible. In this dataset, the post-August-gap advance was followed by a September range-bound phase. That is one past example, not a reliable pattern. The reference levels, in order, are the 10-EMA at 212.13, the 10-16 low at 204.0, the Bollinger middle at 199.84 and the daily SuperTrend stop at 195.85. None of these have been validated as support, and I'm only citing them as indicator-derived or observed prices. 3. Momentum failure signals: MACD rolling over while price makes highs, OBV failing to confirm, a fall in ADX with price stalling, or a close below the daily SuperTrend stop (195.85). A weekly SuperTrend flip below 160.05 would be a primary-trend change.

Event risk: The three largest-volume gap sessions (05-01, 08-07, and the 2025-10-30/31 volume spike) suggest this stock is prone to event gaps. I don't have an earnings calendar. The trader should check for any report date in the coming days or weeks. ATR understates gap risk, because the 08-07 gap was about +35%.

10. Summary table¶

Item	Reading (2026-10-21)	Interpretation
Close / High of day	226.83 / 227.36	Highest close and high in the 252-row window. Bar may be partial (volume 1.43M).
10 EMA / 50 SMA / 200 SMA	212.13 / 188.14 / 115.40	Fully bullish stack. Close is +6.9% / +20.6% / +96.6% above them.
SuperTrend weekly (primary)	UP, stop 160.05 (+41.73%)	Primary trend up. About 7.2 ATR of room.
SuperTrend monthly	UP, stop 75.43 (+200.75%)	Regime up.
SuperTrend daily	UP, stop 195.85 (+15.83%)	Entry timeframe up. About 3.35 ATR to the stop.
ADX	41.74 (10.22 on 10-02)	Strong, strengthening trend. +DI/−DI not checked.
RSI	70.03	At the overbought threshold. Highest in 30 days, no divergence. Sensitive to a partial bar.
MACD / Signal / Histogram	10.54 / 8.87 / +1.68	Bullish and expanding. Line is below its 09-21 level (11.96), a mild unconfirmed divergence.
Bollinger (L / M / U)	171.08 / 199.84 / 228.60	Close is 1.77 below the upper band (%B about 0.97).
ATR	9.24 (about 4.1% of price)	Stable but high volatility. Gap risk is not captured.
OBV	−71.46M (60-day high)	Confirms price. Rally volume is light compared with earlier legs.
TD-9 (W / M / D)	−3 / −5 / −9	Daily exhaustion complete. Weekly and monthly have room. My check suggests the daily 9 has persisted since about 10-13.
Z-score (W / M / D)	+1.50 / +1.33 / +1.88	Elevated but below the 2.0 stretch threshold.
Key levels to monitor	228.60 (upper band), 212.13 (10 EMA), 204.0 (10-16 low), 199.84 (Bollinger mid), 195.85 (daily stop), 160.05 (weekly stop)	Indicator-derived or observed prices, not validated support or resistance.
Main risks	Short-term overextension, light rally volume, event gaps, partial final bar	Verify the earnings calendar and the final close.
Data limitations	No +DI/−DI, news, fundamentals or earnings calendar	The deciding agent should add these.

Bottom line from the tools: The trend is strongly up across weekly, monthly and daily timeframes, and volume confirms it. The daily timeframe is stretched: RSI at 70, a completed daily TD 9, price near the upper band and a z-score of 1.88. The decision on how to act is left to the next agent.

Sentiment Analyst¶

Overall Sentiment: Mildly Bullish (Score: 6.0/10) Confidence: Low

SCOPE AND DATA QUALITY: This read for TEAM (Atlassian Corporation) covers 2026-10-14 to 2026-10-21 and rests on one of three sources. The Yahoo Finance news feed returned DATA_UNAVAILABLE (no articles tagged TEAM). That says nothing about the stock, and no news sentiment is estimated here. Reddit was skipped by configuration, so r/wallstreetbets, r/stocks and r/investing are silent. The only usable input is 30 StockTwits messages (2026-10-15 15:19Z to 2026-10-21 18:14Z). Only 3 of them carry a user sentiment tag. Confidence is therefore low.

1) SOURCE-BY-SOURCE BREAKDOWN News (Yahoo Finance): unavailable. Analyst price-target changes appear only second-hand in a StockTwits post, so they are not confirmed by a news feed here. StockTwits: the tag count is Bullish 3 (10%), Bearish 0 (0%), Unlabeled 27, out of 30. The 3-0 tagged skew is statistically almost meaningless, and 90% of posts carry no label. One of the three Bullish tags (@Ziggy11) is mainly about $ZS, with $TEAM as a co-tagged ticker. That leaves effectively two TEAM-specific bullish tags (@MadMaverick, @DividendDegen). The absence of Bearish tags does not mean no bears. At least one untagged post is explicitly bearish. My own subjective read of the 27 untagged posts plus the 3 tagged ones (not a classifier output): about 14 opinion posts lean constructive. About 6 are factual or informational items with a positive tone (two 52-week-high bot posts, a news link, an analyst-target recap, a leaderboard mention). About 4 are cautious or bearish-leaning, and about 6 are neutral, ambiguous or empty. The constructive-to-cautious ratio is therefore roughly 3.5:1 on opinion posts, with a thin sample. Notable evidence: @AP142367 (Oct 21) says the stock is now '220 plus' after being bought at 160 and ridden down to the 80s. @Stocktwits52wHighs flagged new 52-week highs on Oct 16 and Oct 21. @SuperGreenToday (Oct 20) cites a share price of $214.66. @MadMaverick cites TEAM +136% over the past quarter. @KryptonResearch14 cites target raises: KeyCorp to 235 from 185 (overweight), Barclays to 222 from 172 (Oct 13) and Mizuho to 235 from 215. The same post says the MarketBeat consensus average of 198.59 is still below the stock price. @SeanDavid cites revenue +28% to $1.77B, Rovo ARR growing 2x faster than non-Rovo, GAAP profit of $139M, and a valuation of 7.1x sales versus a 9.8x 3-year average. These figures are user-reported and I could not verify them. Reddit: no data (disabled by config).

2) CROSS-SOURCE DIVERGENCES AND ALIGNMENTS No news-versus-social comparison is possible because news is unavailable. Within StockTwits there are three tensions. (a) Price action and analyst momentum are strongly positive, yet several users say they are nervous about the run-up into earnings (@amgriswo, @BuyHighSellLowGER on Oct 15 'afraid this will go back to 150$ after earnings'). (b) Retail price expectations ($260 gap on earnings, 'clears $300' from @wicbal) sit well above the quoted consensus target of ~$198.59 and the recent raised targets of 222–235. Retail is more aggressive than the sell-side numbers cited. © The tag skew (3 Bullish, 0 Bearish) is more one-sided than the untagged text, which includes a short-setup comment (@PencilNeckGeek, Oct 16) and a technical-resistance warning (@Sambong, Oct 18). Aligned signals: the new highs, the analyst target raises and the 'quality software' commentary all point the same way.

3) DOMINANT NARRATIVE THEMES - Momentum and 52-week highs: the stock has roughly tripled off lows in the 60s–80s (levels cited by users) to about $215–$220+. It is a leaderboard name (@satsandstocks) and the subject of a StockTwits news piece on 52-week highs. - Hindsight regret and FOMO: @IM_AP sold 1,500 shares at 86 and feels terrible. @STEVECOHEN1986 says he should have invested rather than traded. @Iwannagofast1 and @AP142367 refer to the mid-60s and 80s lows. This kind of sentiment often marks a late-stage rally, though it is not predictive. - 'AI kills SaaS' counter-narrative: @SeanDavid frames Atlassian (Rovo AI) as a counterexample. @ThisIsStevenW notes 100–250% gains across software names (TEAM, OKTA, CRWD, TWLO), and $NOW and $ZS are mentioned. The software rebound looks sector-wide, not TEAM-specific. - Relative strength: @BuyHighSellLowGER (Oct 20) likes TEAM's strength while other names are underwhelming in October. - Pre-earnings positioning: expectations are split between a big gap up ($260–$300) and a sell-the-news drop (back to $150).

4) CATALYSTS AND RISKS SURFACED BY THE DATA Catalysts: the upcoming earnings report (users discuss it as imminent, but the exact date is not given in the data), continued analyst target increases (three cited in about a week), and the AI/Rovo monetization story. Risks: the run-up raises the bar into the print, and some users expect a sell-the-news reaction. The price is above the quoted consensus target. A user flags long-term downtrend resistance, and another posts a short setup. Several posts are promotional or low-information, including an options-selling-style alert linking to an external site, duplicate bot posts and empty posts, which inflates apparent activity. A momentum-heavy, software-wide rally is also vulnerable to a sector pullback. Data gaps: no news, no Reddit, no price or volume data, and only 3 sentiment-tagged messages. The sentiment signal is directional, not high-conviction, and it should be weighed alongside fundamentals and technicals.

5) SUMMARY TABLE | Signal | Direction | Source | Supporting evidence | |---|---|---|---| | New 52-week highs / strong momentum | Bullish | StockTwits | Bot posts Oct 16 and Oct 21; price ~$214.66 (Oct 20) to '220 plus' (Oct 21); +136% past quarter per @MadMaverick | | Analyst target raises | Bullish | StockTwits (second-hand) | KeyCorp 235 from 185, Barclays 222 from 172, Mizuho 235 from 215; consensus 198.59 per MarketBeat is below price | | Tagged sentiment ratio | Bullish, very low sample | StockTwits | 3 Bullish / 0 Bearish / 27 unlabeled of 30; one tag mainly about $ZS | | AI-resilience / fundamentals thesis | Bullish | StockTwits (@SeanDavid) | Revenue +28% to $1.77B, GAAP profit $139M, 7.1x sales vs 9.8x 3-year average (unverified) | | Pre-earnings anxiety | Cautious | StockTwits | @amgriswo nervous; @BuyHighSellLowGER fears a return to $150 | | Technical resistance / short setup | Mildly bearish | StockTwits | @Sambong long-term downtrend resistance; @PencilNeckGeek short setup (Oct 16) | | Retail price targets | Very bullish, aggressive | StockTwits | @wicbal $260 gap and $300 after earnings, vs consensus ~$198.59 | | Hindsight regret / FOMO | Late-stage rally flavor | StockTwits | @IM_AP sold at 86; @STEVECOHEN1986 and @Iwannagofast1 comments | | News flow | Unavailable | Yahoo Finance | DATA_UNAVAILABLE, no articles tagged TEAM | | Reddit | Unavailable | Reddit | Skipped by config |

News Analyst¶

TEAM (Atlassian Corporation): News and Macro Report, week of 2026-10-14 to 2026-10-21¶

1. Data coverage¶

Source	Status
Company news for `TEAM`	Unavailable. Two attempts (1-week and 1-month windows) returned "no news articles tagged TEAM". This says nothing about the company. I have no company-specific headlines, earnings details, guidance, analyst actions or insider activity.
FRED macro data (fed funds, 10Y, yield curve, CPI, core PCE, unemployment, VIX)	Unavailable. All 9 calls failed with a vendor parsing error. I have no verified rate levels, yields, inflation or labor figures, and I haven't estimated any.
Global news	Available, but headline and link only. There are no article bodies, so I can't verify details or magnitudes.
Prediction markets (Polymarket)	Available for macro and AI themes. There are no markets on Atlassian.

The macro picture below rests on prediction-market pricing and headlines only. The second point matters most for TEAM and is the weakest part of this report. A downstream agent should not treat it as a full fundamental or technical read.

2. Macro: what the prediction markets say¶

Fed policy: a hold at the October meeting is the base case, but hike risk is priced. - The market on the October 2026 FOMC meeting resolves 2026-10-29. It prices "no change" at 86% ($15.3M volume). That is up 18pp on the week. - A 25 bp hike is priced at 12% ($12.0M volume). That is down 18pp on the week, so it was roughly 30% a week ago. - A 25 bp cut and a 50+ bp cut are each at about 0%. A 50+ bp hike is also about 0%. - "No dissent" is priced at only 24% (thin volume, down 11pp), which suggests the committee may be divided. - "No Fed rate cuts in 2026" is priced at 97% ($9.0M volume). Markets for 6 to 12 cuts in 2026 are all at about 0%.

Two things follow. There is no easing impulse for the rest of 2026. And the tail risk has moved from hike toward hold in the past week, though a hike is still not negligible. I can't tell you the current fed funds level, because the FRED pull failed.

Recession and growth. - US recession by end-2026 is priced at 8% ($2.3M volume). That is a low probability. - UK recession is at 6% and Japan at 4%. Both are very thin markets (under $16K volume), so give them little weight.

AI-cycle sentiment. - "AI bubble burst in 2026" is at 9% ($2.5M volume), up 3pp on the week. - "AI bubble burst by June 30, 2027" is at 20%, but volume is very thin ($36K). - The market sees a low near-term chance of a bust, but the odds are drifting up.

3. Global market and sector headlines (headline-level only)¶

Earnings season is under way. Meta and Tesla report this week, and an IBM Q3 preview expects about 8% EPS growth. Pre-bell coverage describes stocks rising.
AI and chip strength. Stocktwits and others report Nasdaq and S&P futures climbing after a "blowout quarter" at SpaceX, with AI and chip names (SMCI, CRWV, BE) in focus. I can't verify the details from headlines alone.
Software and AI narrative.
"Model Moats: The Vanishing Weight and the Price of the Watt" (Forkast) points to a debate about whether AI models are defensible. That debate bears on application-software valuations.
Procore is partnering with IBM on AI-enabled asset management. This is another sign of incumbents embedding AI into enterprise workflows.
Barron's has a piece on IBM trying to "rewrite its narrative" through earnings.
Zoom is listed among the biggest market-value losers since 2021 (CFO.com, with PayPal and Nike). Zoom is a pandemic-era collaboration and workplace-software peer. This is only a sentiment read-through for TEAM, and I have no TEAM price data to compare.
Commodities. Gold futures are edging up while oil slips (WSJ). That is consistent with a mild defensive or inflation-hedge bid and softer energy costs, but no levels were provided.
Speculative tech (Rigetti, IonQ, D-Wave/QBTS): headlines describe sharp drawdowns, with IonQ down about half in a year. That points to a risk-selective market.

4. Implications for `TEAM`¶

These are conditional inferences, not company-specific evidence.

Rate sensitivity. TEAM is long-duration growth software. A market with no cuts priced for 2026 and a live hike tail removes a valuation tailwind. The week's drop in hike odds (about 30% to 12%) is mildly supportive. The October 28–29 FOMC decision and press conference are the main macro event risk.
Low recession odds (8%) support enterprise IT budgets and seat-based demand. That is a modest positive for collaboration and developer-tooling spend.
AI disruption versus AI beneficiary. The "model moats" and AI-integration headlines show the market debating whether AI erodes or strengthens application-software franchises. Seat-based collaboration tools are often placed in the exposed group. I have no TEAM-specific evidence on which way it falls.
Earnings read-through. Large-cap tech reports this week (Meta, Tesla, IBM). Their AI capex and enterprise-demand commentary could move software multiples.
Possible TEAM earnings date. From background knowledge (not from a tool), Atlassian has historically reported fiscal Q1 results in late October or early November. This could fall within days of the FOMC. Please confirm the date, because it is the largest TEAM-specific catalyst and I couldn't verify it.

5. Gaps to fill¶

TEAM news, earnings date and consensus, guidance, and analyst rating or price-target changes.
Verified FRED data: fed funds level, 10Y yield, yield-curve slope, CPI and core PCE trend, unemployment, and VIX.
TEAM price action and technicals, and peer comparisons (for example MSFT, NOW, CRM, MNDY).

6. Summary table¶

Category	Item	Evidence	Reading for `TEAM`
Data gap	`TEAM` company news	Unavailable (2 attempts)	No company-specific catalyst can be confirmed
Data gap	FRED macro (9 calls)	Vendor error	No verified rate, yield, inflation or labor figures
Fed	Oct 28–29 FOMC	Hold 86% (+18pp wk), hike 12% (−18pp wk), cut about 0%	Event risk. A hold is the base case and the hike tail has shrunk
Fed	2026 path	"No cuts in 2026" 97%	No easing tailwind for growth multiples
Fed	Committee unity	"No dissent" 24% (−11pp, thin)	Possible hawkish or dovish surprise in the statement or dissents
Growth	US recession by end-2026	8%	Supports enterprise IT budgets
AI cycle	AI bubble bursts in 2026	9% (+3pp wk)	Low but rising risk to the sector narrative
AI cycle	Bubble bursts by Jun 2027	20% (thin volume)	Low-confidence signal
Earnings	Meta, Tesla, IBM this week	Headlines	Read-through on AI capex and enterprise demand
Sentiment	Futures up on AI and chip strength	Headlines (SpaceX, SMCI, CRWV)	Risk-on in AI hardware. Unclear for software
Sector	"Model moats" debate; Procore–IBM AI tie-up	Headlines	Disruption versus beneficiary debate for application software
Peer	Zoom among largest value losers since 2021	CFO.com headline	Cautionary read-through for pandemic-era collaboration names
Commodities	Gold up, oil down	WSJ headline, no levels	Mild defensive or hedging bias, softer energy costs
Catalyst	`TEAM` fiscal Q1 earnings	Unverified, from background knowledge	Likely the biggest `TEAM`-specific event. Confirm the date

Fundamentals Analyst¶

TEAM (Atlassian Corporation): Fundamental Research Report¶

As of 2026-10-21 | Technology / Software – Application | NMS

Scope note: The tools returned no new filings or insider transactions dated within the last 7 days. The latest insider filing is 2026-10-12. The latest balance sheet is FY-end 2026-06-30. Quarterly income and cash flow statements stop at 2026-03-31. This report therefore covers the most recent complete picture, which is FY2026 (year ended 2026-06-30) plus insider activity through mid-October. Figures marked (derived) or (inferred) are my own arithmetic, not tool outputs. Treat them as less certain.

1. Snapshot and market data¶

Metric	Value	Comment
Market cap	~$57.4B
Implied price (inferred)	~$227	P/B 54.3 × book value $4.177, and forward PE 33.65 × forward EPS $6.74. Both give about $227.
52-week range	$56.01 – $227.36	The implied price is at the top of the range, roughly 4x the low.
50-day / 200-day average	$186.68 / $115.03	Price is about 21% above the 50-day and about 97% above the 200-day average.
Beta	1.228	Above-market volatility
Forward P/E	33.65	On forward EPS of $6.74, which is almost certainly non-GAAP
PEG	2.17
TTM EPS (GAAP)	–$0.21	Still loss-making on a GAAP basis
Price/Book	54.3	Distorted by a thin equity base (see section 4)
Price/Sales (TTM)	~8.7x	$57.4B / $6.57B (derived)
Dividend yield	0%

The share count is about 253–256M, from market cap divided by price and from net loss divided by EPS. The stock has re-rated sharply. Insider sale prices were about $80–95 in Feb–May 2026, about $162–175 in mid-August, $190 on 8/28 and $210 on 10/12.

2. Income statement¶

Annual history (USD millions)¶

FY (Jun)	Revenue	YoY	Gross profit	GM	Operating income	Op margin	Net income	Diluted EPS
2021	2,089	–	1,757	84.1%	141	6.7%	–579	–2.32
2022	2,803	+34.2%	2,350	83.8%	70	2.5%	–520	–2.05
2023	3,535	+26.1%	2,901	82.1%	–345	–9.8%	–487	–1.90
2024	4,359	+23.3%	3,555	81.6%	–117	–2.7%	–300	–1.16
2025	5,215	+19.6%	4,320	82.8%	–130	–2.5%	–257	–0.98
2026	6,572	+26.0%	5,575	84.8%	+10	0.2%	–54	–0.21

Growth re-accelerated. Growth went from 19.6% in FY25 to 26.0% in FY26 on a $5B+ revenue base.
Gross margin is at a six-year high. It was 84.8% in FY26 versus 81.6% at the FY24 trough.
GAAP operating income turned positive for the first time since FY22. FY26 came in at +$10M, after a –$345M low in FY23. The net loss narrowed from –$487M in FY23 to –$54M in FY26.

Quarterly trend (USD millions; * = derived as FY total minus Q1–Q3)¶

Quarter end	Revenue	YoY	Gross margin	Op income	Net income	EPS
2024-09	1,188	–	81.6%	–32	–124	–0.48
2024-12	1,286	–	82.7%	–57	–38	–0.15
2025-03	1,357	+14.1%	83.8%	–12	–71	–0.27
2025-06*	1,384	–	83.1%	–29	–24	n/a
2025-09	1,433	+20.6%	82.0%	–96	–52	–0.20
2025-12	1,586	+23.3%	85.1%	–48	–43	–0.16
2026-03	1,787	+31.7%	85.3%	–56	–98	–0.38
2026-06*	~1,766	~+27.6%	~86.5%	~+210	~+139	~+0.53

Q4 FY26 (derived). Revenue growth stayed near 28%. The data imply a large swing to GAAP profitability: - Operating income of about +$210M, roughly a 12% margin. This matches the fundamentals feed's 12.26% operating margin. - Net income of about +$139M and EPS of about +$0.53.

This needs scrutiny. Revenue was flat to slightly down sequentially (about $1,766M versus $1,787M). Operating expense fell by roughly $260M quarter on quarter (derived). That points to one-time items in Q3 or Q4, such as restructuring, acquisition charges or stock-comp adjustments. It could also be a data or tagging issue. The FY26 10-K and earnings release should be checked before treating about 12% as a run-rate GAAP margin.

3. Cash flow¶

Annual (USD millions)¶

FY	Operating CF	Capex	FCF (derived)	FCF margin	Investing CF	Financing CF
2021	790	32	758	36.3%	259	–1,603
2022	821	71	750	26.8%	37	–399
2023	868	26	842	23.8%	–1	–148
2024	1,448	33	1,415	32.5%	–964	–408
2025	1,460	45	1,415	27.1%	–342	–783
2026	1,353	34	1,319	20.1%	–807	–1,800

Key observations - Cash generation did not follow revenue. Revenue grew 26% in FY26, but operating cash flow fell about 7% and FCF fell about 7%. FCF margin dropped from 32.5% (FY24) to 20.1% (FY26). That is the main fundamental concern in this dataset. The tools don't say why. Possible drivers are acquisition-related costs, cash taxes and working capital. - The business is capital-light. Capex is only about 0.5% of revenue. - FY26 cash use outran cash generation. Financing outflows were $1.8B and investing outflows were $807M, against $1.35B of operating cash flow. Cash fell by about $1.27B. - December 2025 quarter. Investing outflow was –$1,144M, consistent with acquisition activity. The tools do not confirm this. - March 2026 quarter. Financing outflow was –$991M and investing inflow was +$404M. Equity fell sharply that quarter (see section 4). This is consistent with a large buyback, though not confirmed. - Derived Q4 FY26. Operating cash flow was about $479M and FCF about $474M, up about 28% on Q4 FY25 (about $375M).

4. Balance sheet¶

USD millions	FY2024	FY2025	FY2026	Change YoY
Total assets	5,212	6,042	6,104	+1%
Cash & equivalents	2,177	2,513	1,240	–51%
Current assets	3,076	3,891	2,797	–28%
Current liabilities	2,610	3,181	3,571	+12%
Total liabilities	4,179	4,696	5,045	+7%
Stockholders' equity	1,033	1,346	1,058	–21%

Quarterly equity path: 1,379 (Sep-25) → 1,591 (Dec-25) → 879 (Mar-26) → 1,058 (Jun-26). The roughly $710M drop in March 2026 was far larger than the quarter's –$98M net loss. This is consistent with heavy share repurchases (inferred).

Ratios (from fundamentals) - Current ratio 0.78. That is 2,797 / 3,571, so current liabilities exceed current assets. This is common for subscription software, where deferred revenue sits in current liabilities. Still, cash is lower and the ratio is below 1. - Debt/equity 1.16x. This implies about $1.2B of debt (inferred). Cash is about $1.24B, so cash and debt are roughly in balance. The tool does not break out debt or short-term investments, so net cash can't be verified. - Return on equity –4.5%, return on assets +3.0%. - Price/Book of 54x reflects a small equity base, partly because of buybacks and accumulated deficits. It is not a meaningful valuation signal.

5. Insider transactions¶

The tool output covers 2025-11-19 to 2026-10-12 and appears capped at 150 rows. Earlier activity is not visible.

Co-founder selling (the dominant flow)¶

CEO Michael Cannon-Brookes and director / >10% holder Scott Farquhar. Each sold exactly 7,665 shares per trading day, mirror-matched, on 53 trading days from 2025-11-20 to 2026-02-06. That is about 406K shares each.
Value. Summing the listed rows gives roughly $59M each, or about $118M combined. Prices ranged from about $148–165 in Nov–Dec, to $120–160 in January, to $93–108 in early February.
Interpretation. The uniform daily size is characteristic of a pre-arranged selling plan, not discretionary timing. It is therefore weaker as a sentiment signal. The ownership flag is "I" (indirect).
No Cannon-Brookes or Farquhar sales appear after 2026-02-06, so none during the rally from about $100 to about $227.
Data quirks. Row 74 labels Cannon-Brookes "Chief Financial Officer" on 2026-01-05, which is a mislabel. Rows 77–78 show 467,565 shares each on 2026-01-02 with no price or transaction type. That is probably a holdings or transfer entry.

Officers (periodic, vest-linked)¶

Sales cluster mid-month in Feb, May, Aug and Nov, consistent with quarterly vest or tax-related sales.
Brian Duffy (officer).
Sold about $1.24M on 8/14 and $0.32M on 8/19.
Sold $0.57M and $0.28M in June, and $0.57M and $0.17M in May.
Received a grant of 121,512 shares on 4/23 and 51,549 shares on 9/18.
James Chuong (CFO).
Received a 297,030-share grant on 2026-04-02, probably new-hire or retention equity (inferred).
Sold $1.56M on 8/19 and $0.78M on 5/19.
Received 6,374 shares on 9/18.
Joseph Binz appears as CFO in Nov-25 and Feb-26 sales, then disappears. Chuong appears as CFO from April. This points to a CFO transition in roughly Feb–Apr 2026 (inferred; verify).
Rajeev Rajan (CTO) sold about $0.33M and $0.25M in Feb 2026.
Gene Liu (officer) made price-tiered sales at round prices.
8/19: 1,125 shares at $175.00 (about $197K).
8/28: 939 shares at $190.00 (about $178K).
10/12: 337 shares at $210.00 (about $71K).
This looks like a limit-price ladder, so further sales are possible if the stock rises. It is a small amount.
Total officer sales from Aug 14 to Oct 12 are about $3.8M, which is small against a $57B market cap.

Directors¶

Only open-market purchase in the dataset: Scott Belsky (director) bought 1,672 shares at $148.03 (about $248K) on 2025-12-01. It is small, but it is the only insider buying in the file.
On 2025-12-02, nine directors each received 1,885 shares, the annual grant. Anil Sabharwal received 2,118 shares on 2026-02-02.
Shona Brown sold 528 shares at $163 (about $86K) on 2025-12-12.

Net read: Insider activity is overwhelmingly selling, but it is plan-driven and mechanical. There is no discretionary buying beyond one small director purchase. Nothing in the last 9 days.

6. Data-quality flags¶

#	Issue	Why it matters
1	FCF mismatch. The fundamentals feed shows FCF of $1,655M, but SEC cash-flow data give $1,353M – $34M = $1,319M for FY26.	Valuation based on FCF differs by about 25%. Use the SEC-based figure as the conservative one.
2	Gross profit. The feed shows $5,629M, versus $5,575M in the annual statement.	About 1% difference, minor.
3	Q4 FY26 sequential oddity. Revenue is flat to down versus Q3, yet operating income swings by about +$266M.	Possible one-time items or tagging error. Verify before extrapolating.
4	No Q4 quarterly rows in the quarterly income and cash-flow endpoints.	I derived Q4 as the annual figure minus Q1–Q3.
5	Q1 FY27 (quarter ended 2026-09-30) is not in the data.	The next earnings release is the key catalyst. Confirm the date.
6	Operating margin of 12.3% in the feed is the latest quarter only. The FY26 GAAP margin is 0.2%.	Don't confuse the two.
7	Insider table is truncated at 150 rows, with the title mislabel noted above.	The full selling history is not visible.

7. Takeaways for traders¶

Supportive factors - Revenue growth re-accelerated to about 26% for FY26, with about 28–32% in the last two quarters, on a base above $6.5B. - Gross margin is about 85%, a multi-year high. - GAAP operating income turned positive for FY26, and the derived Q4 run-rate is about +12%. - The net loss has narrowed every year, from –$579M in FY21 to –$54M in FY26. - Free cash flow is still about $1.3B and capex is minimal. - Insider selling since February is small and mostly routine.

Risk factors - Valuation is full. The stock trades at about 8.7x sales, about 34x forward non-GAAP earnings, about 43x SEC-based FCF (about 35x on the feed's FCF), and a PEG of 2.2. The price is at the top of the 52-week range and about 4x the low. - FCF margin has compressed from 32.5% to 20.1% in two years, while revenue grew. Operating cash flow fell in FY26. - Liquidity is thinner. Cash is down 51%, the current ratio is 0.78, debt/equity is 1.16x and equity fell 21%. The company spent more than it generated (financing and investing outflows of about $2.6B versus $1.35B of operating cash flow). - GAAP earnings quality is uncertain. The Q4 swing needs verification, and TTM GAAP EPS is still negative. - Management change. The apparent CFO transition and large executive equity grants are worth checking. - Overextension. The price sits far above both moving averages. Beta is 1.23.

Items to check next 1. The FY26 10-K and Q4 release: one-time items, SBC, restructuring, acquisition costs, the debt schedule, buyback totals and deferred revenue. 2. The Q1 FY27 earnings date and guidance. Does FCF margin stabilize and does GAAP operating margin hold above zero? 3. New Form 4 filings. Does Cannon-Brookes or Farquhar resume sales near highs, and do the Gene Liu tiered sales continue above $210?

8. Summary table¶

Category	Key point	Data / evidence	Implication
Identity	Atlassian Corporation (TEAM), Software – Application, NMS	Fundamentals	Large-cap SaaS, beta 1.23
Valuation	Premium multiples	Market cap $57.4B; P/S ~8.7x; forward P/E 33.7; PEG 2.17; P/FCF ~35–43x	Priced for continued growth and margin expansion
Price action	Near 52-week high	~$227 vs range $56.01–$227.36; 50-day $186.7; 200-day $115.0	Strong momentum; extended vs averages
Revenue	Re-accelerating	FY26 $6,572M (+26%); Q3 +31.7%; Q4 ~+27.6% (derived)	Growth thesis intact
Gross margin	Expanding	84.8% FY26 vs 81.6% FY24; Q4 ~86.5% (derived)	Strong unit economics
GAAP profitability	Just turned positive	FY26 op income +$10M; net loss –$54M; EPS –$0.21; Q4 op income ~+$210M (derived)	Verify one-time items
Free cash flow	Large but shrinking margin	FY26 FCF ~$1,319M (20.1% margin) vs 32.5% in FY24; feed shows $1,655M	Key concern
Cash flow use	Outflows exceed OCF	FY26 OCF $1,353M; investing –$807M; financing –$1,800M	Cash drawdown
Balance sheet	Weaker liquidity	Cash $1,240M (–51%); current ratio 0.78; D/E 1.16x; equity $1,058M (–21%)	Less cushion
Equity dynamics	Sharp Q3 FY26 drop	Equity 1,591 → 879 in Mar-26 quarter; financing –$991M	Consistent with heavy buyback (inferred)
Insider selling	Founder plan sales	Cannon-Brookes and Farquhar: 7,665 shares/day each, 53 days to 2026-02-06; ~$59M each	Plan-driven; none since Feb
Officer activity	Routine sales and grants	Aug–Oct sales ~$3.8M; Gene Liu tiered sales at $175/$190/$210; Chuong 297K-share grant (Apr)	Small relative to market cap
Insider buying	Minimal	Belsky: $248K at $148.03 on 2025-12-01	Only open-market buy in file
Management	Probable CFO change	Binz (through Feb-26) → Chuong (Apr-26)	Verify context
Data gaps	Source inconsistencies	FCF mismatch; Q4 sequential oddity; truncated insider list; no Q1 FY27 data	Cross-check primary filings
Next catalyst	Q1 FY27 results	Quarter ended 2026-09-30, not yet in data	Confirm date and watch FCF margin

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for TEAM (Atlassian): The Business Re-Accelerated, and the Market Is Catching Up

The bear is going to open with "it's up 4x, it's overbought, it's expensive." I'll start with the business, because the stock is only at $226.83 because the fundamentals turned.

1. Growth is accelerating at scale¶

Revenue growth: FY26 revenue was $6.57B, up 26.0%, after 19.6% in FY25. Quarterly growth was +20.6%, +23.3%, +31.7%, then roughly +28% in the June quarter (derived).
Why this is rare: Software companies at this size usually decelerate. TEAM added about $1.36B of revenue in a year on a base that was already above $5B, and growth went up rather than down.
Rule of 40: 26% growth plus a 20.1% FCF margin is about 46 (derived), comfortably above the benchmark.

2. Profitability is turning¶

Gross margin: 84.8% in FY26, up from the 81.6% trough in FY24. The derived Q4 figure is about 86.5%.
GAAP operating income: It was +$10M in FY26, the first positive year since FY22, after a –$345M loss in FY23.
Net loss: It has narrowed every year, from –$579M in FY21 to –$54M in FY26.
Free cash flow: About $1.3B on 0.5%-of-revenue capex. This is a cash-generative business, not a story stock.

3. The bear's best fundamental point has an answer¶

The bear will say FY26 FCF fell about 7% while revenue grew 26%, and that FCF margin dropped from 32.5% to 20.1%.

It's a real compression, and I'm not hiding it. But the derived Q4 FCF was about $474M, up roughly 28% year on year. That is the first quarter in this dataset where cash flow growth matched revenue growth. If the Q1 FY27 print confirms it, the compression narrative breaks.
The cash drawdown (–51% to $1.24B) looks like capital allocation, not distress. Equity fell from $1,591M to $879M in the March quarter, against a net loss of only $98M. That is consistent with a large buyback (my inference, unconfirmed). If so, management bought stock when it traded far below today's price. The current ratio of 0.78 is typical of subscription software, where deferred revenue sits in current liabilities.

4. The AI narrative cuts in TEAM's favor so far¶

The fear all year was "AI kills seat-based SaaS," and the 67% drawdown to $57 reflected it. What happened instead:

Growth re-accelerated after the drawdown. That is the opposite of what the disruption thesis predicts.
One user reports Rovo ARR growing 2x faster than non-Rovo. I can't verify that and won't lean on it. The reported revenue and margin numbers are consistent with it.
The recovery came in event-driven gaps. The 05-01 gap was +29.6% on 27.4M shares, and the 08-07 gap was +35.3% on 20.1M shares. That looks like institutions repricing on results, not retail momentum.

5. Technicals show a trend, not a blow-off¶

Trend alignment: All three SuperTrend tiers are up. The MA stack is fully bullish (price > 10 EMA 212 > 50 SMA 188 > 200 SMA 115).
Trend strength: ADX is 41.7 and rising.
Volume confirmation: OBV is at a 60-day high with price, so there is no divergence.
Weekly and monthly TD counts: They are only –3 and –5 of 9. The daily 9 is a short-term flag. The higher timeframes aren't close to exhaustion.
Weekly z-score: +1.50, well below the 2.0 stretch threshold.
Room to the weekly stop: About 7.2 ATR.

RSI at 70.03 is a threshold touch, not a divergence. RSI made a higher high with price.

6. Sell-side and macro are still catching up¶

Targets are chasing price. KeyCorp moved to $235 from $185, Barclays to $222 from $172, and Mizuho to $235 from $215 (second-hand via StockTwits). The cited consensus of about $198.59 is below the current price, so more revisions look likely if fundamentals hold.
Insider selling is mechanical. The founders' sales ran at exactly 7,665 shares per day each, which looks like a pre-arranged plan. It stopped on 2026-02-06 and has not resumed during the rally from about $100 to $227. Officer sales from Aug to Oct total about $3.8M against a $57B market cap, and a director bought $248K on the open market.
Macro is benign. US recession odds are 8%. Hike odds for the October FOMC fell from about 30% to 12% in a week, and a hold is priced at 86%.

Where the bear has a point¶

Valuation is full. It's about 8.7x sales, 33.7x forward non-GAAP P/E, and 35–43x FCF. That is demanding.
The Q4 GAAP swing needs checking. Revenue was flat sequentially while operating income rose by about $266M. It could be one-time items. I'd want the 10-K before calling 12% a run-rate margin.
Earnings are close, and the date is unconfirmed. A gap of 30%+ has happened in both directions' worth of volume, and ATR understates gap risk.
Rally volume is light. October's advance ran on 1.4M–3.7M shares a day.
The rebound looks sector-wide. Social chatter cites 100–250% gains across other software names. Some of this is beta.
The latest bar may be partial. Volume was only 1.43M.

Why I'm still constructive¶

The bear's case is mostly about price: overbought, extended, crowded into earnings. Those are reasons to size sensibly and use the 10 EMA ($212) or the daily SuperTrend stop ($195.85) as risk lines. They aren't reasons to think the business is weakening. On the evidence here, TEAM has reaccelerated growth, expanded margins, turned GAAP-positive, and kept about $1.3B in annual FCF. A pullback inside an intact weekly trend would be an entry point, not a thesis break. A thesis break would be a weekly close below the $160 SuperTrend stop or a clear miss on Q1 FY27 FCF margin.

So here's my question for the bear: what is your evidence that growth re-acceleration and margin expansion reverse, rather than just that the stock is expensive and extended? Bull Analyst: # Bull Rebuttal for TEAM: You're Pricing the Hurdle Off a Depressed Base

You've sharpened the debate. Your case rests on one assumption: that trailing-twelve-month FCF is the right base for judging the price. I think the data argue against that, and most of your other points follow from it.

What I concede¶

FY26 FCF fell 7% while revenue grew 26%. That is real.
SBC is the true gap between $1.3B of FCF and $10M of GAAP operating income. FCF is not owner earnings.
Stops don't protect you through an earnings gap. Only sizing does.
Price is ahead of verified data. The stock is up 52% from the 08-07 gap with no new statements.
Sell-side targets give almost no upside at this price.

1. The exit rate changes your own hurdle math¶

Your 2.3% yield and 18–23% required FCF CAGR both start from $1,319M. That figure includes a nine-month stretch at a 17.6% FCF margin. Q4 ran at 26.8%. Q4 was about 26.5% of FY25's FCF, so I'll use that seasonal share to avoid just multiplying by four (derived).

	Your base (TTM)	Q4 seasonally adjusted
FCF base	$1.32B	~$1.79B
P/FCF at $57.4B	~43x	~32x
FCF yield	2.3%	~3.1%
CAGR needed to reach your $3.1–3.7B	18–23%	~11–16%

The hurdle from the exit rate overlaps your own historical range. FCF CAGR was 11.7% from FY21. FY21 was the peak-margin year at 36.3%, so that endpoint flatters the bear. From FY22 the CAGR is 15.2%, and from FY23 it is 16.1%.

The revenue path is just as undemanding. If revenue grows 12–15% a year (half the current rate) and FCF margin returns to its FY22–FY25 average of about 27.5%, FCF reaches $3.2–3.6B. That lands inside your range. The market doesn't need heroics. It needs the Q4 cash conversion to persist while growth halves.

The caveats are mine. The seasonal adjustment is an assumption, I'm borrowing your 25–30x exit multiple, and I haven't modeled dilution.

2. The Rule of 40 is flat only on the annual number¶

FY26 was 26.0 + 20.1 = 46.1, as you say. Q4 on its own was 27.6% growth plus a 26.8% FCF margin, about 54 (derived). That is back near FY24's 55.8. It is one quarter, so it proves nothing alone. But your annual-flat reading blends nine compressed months with the quarter that shows where the business is running now.

3. The Q4 swing: the outlier is Q3¶

You called the Q4 operating income swing unexplained. Derived opex (gross profit minus operating income, with gross margin rounding of about ±$10M) by quarter:

Quarter	Q1	Q2	Q3	Q4
Opex ($M)	~1,271	~1,398	~1,580	~1,316

Q4 opex is not a low outlier. It is 3.5% above Q1 and below Q2. Q3 is the high outlier, up about $182M sequentially. That also explains why the nine-month loss widened by $99M. The pattern fits a one-time Q3 charge better than a Q4 accounting gain.

This cuts both ways. Opex roughly flat against revenue up 23% over three quarters is very strong leverage. I agree the 10-K must confirm it. But "Q4 looks too good" and "Q3 looked too bad" are different diagnoses, and the data lean toward the second.

On the CFO: the "transition" is inferred from Form 4 titles. The same dataset labels Cannon-Brookes as CFO on one row. I wouldn't discount a print on that basis.

On SBC, I'm not claiming FCF is clean. The Q4 operating income is after SBC. If even half of that ~12% margin is recurring, SBC leverage is arriving.

4. The exit rate on revenue is not soft¶

Smooth out the quarterly timing. H1 FY26 revenue grew 22.0% year on year ($3,019M vs. $2,474M). H2 grew 29.6% ($3,553M vs. $2,741M). That is acceleration, and it doesn't depend on whether Q3 or Q4 was lumpy.
Holding 28% needs +3.8% sequential growth. Last year's Q4→Q1 was +3.5% ($1,384M to $1,433M). Repeating that gives about $1,828M, or +27.6% year on year. That is essentially the same growth rate.
Your floor case still helps. At flat sequential revenue, Q1 FY27 growth is 23.2%. That beats every FY25 quarter and Q1 FY26's 20.6%.
Inorganic growth looks limited. Q1 FY26 grew 20.6% before the December-quarter investing outflow. One point of year-on-year growth in Q3 is about $13.6M of quarterly revenue. Explaining even 5 points would take about $270M of annualized acquired revenue. That would be a very cheap purchase against a ~$1.14B outflow, and not all of that outflow was necessarily acquisitions. My recollection, not verified here, is that the September 2025 deals were for early-stage or small-revenue companies. The 10-K should break out organic growth, as you ask.

5. The balance sheet shows redeployment, not burn¶

Cash fell $1,273M, but total assets rose 1%. Non-cash assets therefore rose about $1.3B (derived). That is consistent with acquisitions or investments, not cash disappearing. The current ratio drop is mostly the cash drop. Net debt is roughly zero (cash $1.24B against ~$1.2B inferred debt), against $1.3–1.8B of annual FCF. That is under a year of cash flow, so I don't see a liquidity problem.

On the buyback, I agree it is an inference. If the ~$1B March-quarter financing outflow was mostly repurchases at $60–100, it retired roughly 10–15M shares (4–6% of the count). Those shares are worth $2.3–3.4B today. Your point that each dollar now retires fewer shares is true going forward. But it describes a better outcome for existing holders, not a worse one.

6. AI: use a non-lagging indicator¶

I accept that revenue lags. Gross margin is a better test. AI features carry inference costs that land in COGS, and discounting under competition would hit price. Gross margin went from 82.0% in Q1 to about 86.5% in Q4 (derived). If seat compression or AI cost pressure were biting, I'd expect margin to move the other way.

On Zoom, the "value loser since 2021" headline is about multiple compression from a pandemic peak, with growth collapsing. TEAM already took its own 67% reset, and its growth is accelerating. Those are different shapes.

On sector beta, I agree that beta is 1.23 and the rebound is broad. That argues for sizing. It doesn't show the TEAM-specific numbers are wrong.

7. Technicals¶

MACD divergence. MACD is in dollars. 10.54 on a $226.83 price is 4.6% of price. The 09-21 reading of 11.96 on $195.67 was 6.1%. The 26-day EMA has also caught up after the 08-07 gap. Part of this "divergence" is a scaling effect. The line is rising three sessions in a row, with a positive histogram.
Volume. OBV is at a 60-day high, so there is no distribution. I'd also not compare ordinary days with 20M+ gap days.
Valuation vs. history. The 7.1x vs. 9.8x 3-year average comes from a user and is unverified. Even at 8.7x, the stock is still about 11% below that average. Growth over that window averaged roughly 23%, below today's 26%.
Macro. "No cuts" at 97% is old news. The new information this week was hike odds falling from about 30% to 12%, with recession odds at 8%.

8. Your "change my mind" list¶

Conditions 1–3 are all fundamental: Q4 recurrence, Q1 FCF margin expansion, organic growth near 25%. The print and the 10-K will deliver them. Condition 2 may clear almost mechanically. If Q1 FY27 merely holds Q4's 26.8%, it expands against a Q1 FY26 that sat inside a 17.6% nine-month average. I don't have the Q1 FY26 split, so that is likely rather than certain. Condition 4 is a price ask.

This is the cost of waiting. If the evidence arrives and is good, the repricing happens on the day, as it did on 05-01 (+29.6%) and 08-07 (+35.3%). I accept your point that those gaps started from depressed expectations. I'm not forecasting another +30%. But "wait for confirmation" has a price too.

Where I land¶

The business case holds: accelerating growth, expanding gross margin, a plausible GAAP inflection, ~$1.3B of FCF with a better exit rate, and little net debt. The weak point is entry price and event risk. My answer is risk control, not a bearish conclusion:

Size for the gap, not the stop. If a −30% gap should cost no more than ~1% of the portfolio, the position is capped near 3%. A put spread or collar through the print is another way to define the risk.
Add on a pullback. The 10 EMA ($212), the 10-16 low ($204) and the Bollinger midline (~$200) are the staging levels. The daily TD 9, RSI at 70.03 and a possibly partial final bar all support not chasing.
Thesis-break triggers:
Q1 FY27 revenue growth below ~23%
FCF margin falling back toward the nine-month 17.6%
A 10-K showing Q4 operating income was driven by one-time credits
A weekly close below $160

My question back: if Q1 FY27 shows growth near 27% and FCF margin near 27% (the Q4 pattern repeating), is 32x exit-rate FCF still a price you'd refuse for a business growing that fast at 85% gross margin? If it is, your objection is about the multiple, and we should agree on a number. If it isn't, then the print is the only evidence that separates us. Bull Analyst: # Bull Rebuttal for TEAM: What's Left Is One Filing and a Turn or Two of Multiple

You landed several hits. I'll list them, then say what still stands, then answer your closing question.

What you got right¶

My "seasonal adjustment" wasn't one. FY25 ran at 27.1% FCF margin in both the nine months and Q4, so there was no seasonality to adjust for. The $1.79B was Q4's margin applied to the full year. The honest range is $1.32B delivered, about $1.9B if Q4 is the new level ($474M × 4, derived), and less if the nine-month pace is the truth. I'll stop using $1.79B as a base.
The opex leverage was cherry-picked. Over the full year, opex/revenue only moved from 85.3% to 84.7%. About 2.0 of the 2.7-point operating margin gain came from gross margin. A Q3 charge also can't explain Q4 landing $82M below Q2 on 11% more revenue. I won't defend ~12% as a run-rate.
I had the MACD direction backwards. Normalizing by price widens the gap (4.6% vs 6.1%).
Gross margin isn't a demand indicator. It argues against COGS and pricing pressure. It says nothing about seats, NRR or cRPO.
"Very cheap" was wrong. At 4.2x revenue the acquisition wasn't cheap. I also switched yardsticks between Q4 and H1/H2.
The valuation comparison to history is worse on cash. On TTM FCF the stock is at ~43x against ~35x for the 3-year average.

What still stands¶

1. Your own M&A assumption leaves the acceleration mostly intact¶

I'll grant your worst case: the entire $1.14B was M&A at 5–10x revenue. That is $115–230M of annualized revenue, or 2.1–4.2 points of Q4 growth on the $1,384M comp (derived). Q4 organic growth is then about 23.4–25.5%, against 20.6% in Q1 FY26. That is a smaller acceleration than the headline, but still 3–5 points. I don't know that the investing line was all M&A, since it is net of securities flows. I'm granting your assumption, not asserting it.

You're right that Q1 FY27 can't cleanly separate organic from acquired growth. But the acquisition note in the 10-K normally discloses acquired revenue (my expectation, not verified here). That is a task for today.

The same goes for Q4's operating income and SBC. The 08-07 gap was probably the FQ4 report, since the FY26 annual figures are already in our dataset. That is an inference, but it means buyers at $149 saw the full Q4 detail. That doesn't prove they were right. It does mean we can read what they read.

2. In the full-bull case, the valuation gap is one to four turns of multiple¶

Your fair value of $185–205 applies 22–25x to FY27E FCF of $2.0–2.2B. FY27 ends June 2027, and the market prices the next twelve months. Weight three-quarters of your FY27 midpoint ($2.1B) with one quarter of an FY28 near $2.6B, which assumes growth fading to ~20% and a 26–27% margin. NTM FCF is then about $2.2B. All of that is my assumption.

At your 22–25x: $49–56B, or about $195–220 a share.
Each turn of multiple: about $8.80 a share.
Today's price: $227 is about 26x that NTM figure.

So even on your multiple, the stock is roughly 3–16% above fair value if everything goes right. I won't call that cheap. It is a disagreement about one to four turns in the best case. The honest summary is that the price is full if things go right and too high if they don't, which is why structure matters more than conviction.

3. The odds math needs a hedge, and we both said that¶

Your break-even arithmetic is right: 70% at $260, 52% at $300. But $149 is a full unwind of the 52% run, which means a broken thesis. A 24/22 print more plausibly lands around $185–205, the zone you'd buy.

Suppose a collar at $200 put / $260 call were available, which I can't verify without the options chain. Skew on a name with a 4% ATR may force a tighter put or a lower call. Max loss is 11.8%, max gain is 14.6%, and break-even falls to about 45%. That is what I meant by "size for the gap."

Your question: name a print outcome short of a collapse that makes me sell¶

24% growth and a 22% FCF margin. That is a quarterly Rule of 40 of 46, the same as FY26's annual 46.1. If Q1 FY27 shows that, Q4 was not the exit rate. The claim the price rests on is mid-20s growth with cash conversion back in the high 20s, and that print falsifies it. I'd cut at least half the next morning.

You were right that my old triggers were too loose. "Growth below ~23%" meant flat sequential revenue. Here are tighter ones:

Q1 FY27 outcome	Threshold	Action
Quarterly Rule of 40 (growth + FCF margin)	Below 50 (Q4 ≈ 54)	Cut at least half
Reported revenue growth	Below 25% (about $1.79B)	Cut at least half
GAAP operating income	≤ 0 (negative in Q1–Q3, Q4 ≈ +12%)	Q4 was a one-off, so drop the GAAP-turn leg and cut to starter size
10-K read (before the print)	Q4 opex step is one-time credits, or acquired revenue is above ~4 points	Don't initiate

These govern the decision after the print. They don't protect against the gap itself, which is what sizing and the hedge are for. We agree on that.

Where I land¶

Not in dispute: About 85% gross margin, mid-20s reported growth, ~$1.3B of TTM FCF and capex at 0.5% of revenue.
Unresolved: Whether Q4's cash conversion and opex are a run-rate. The 10-K can answer that now, and the print comes next.
Position: No full position at $227.
Starter: About 1.5% (half my 3% cap), only after the 10-K read passes, and hedged through the print.
Remainder: Add only if the print clears the triggers above, or on a pullback to $200–212 (the 10 EMA and Bollinger midline).
If the 10-K fails: I don't initiate, and we agree.
What still separates us: Whether a hedged half-position above your $195–220 zone beats waiting to buy after a miss. I'd rather hold hedged exposure into the event. If the print is clean and the stock gaps to $250+, your entry never shows up.

My question back: is your $185–205 evidence-contingent? If the 10-K shows Q4 operating income was recurring and acquired revenue is under 2 points, does your multiple or range move up? Or is it a price you'd hold to regardless of what the filing says? Bull Analyst: # Bull Closing for TEAM: The Business Is Settled, the Entry Is About Structure

The debate has narrowed. We agree on ~85% gross margin, mid-20s growth, negligible capex, and FCF down 7% in FY26. We also agree that SBC is the real gap to GAAP, that stops don't survive gaps, and that neither of us has read the 10-K. Below are your question, my changes, what I still hold, and the plan.

1. Your question: sell the starter at $250, or does the range move?¶

The range moves with the inputs, not the price. You tie the multiple to evidence yourself: 22-25x as the base, 25-28x if the 10-K is clean and SBC leverage is real. Share count is ~253M, so each $100M of NTM FCF is worth about $10 a share at 26x.

NTM FCF	25x	28x
$2.2B	$217	$243
$2.3B	$227	$255

A clean print plus an FY27 guide at the top of your $2.0-2.2B range (my assumption) gives roughly $2.3B of NTM FCF. At $250 the stock is then 27.5x, inside your clean-case range. Without that guide it is your 28.7x.

My rule is fixed in advance and tied to the multiple, not the price:

Hold through a gap to ~$250. I add nothing.
Trim a third at 28x of the then-current NTM estimate. That is $243 on $2.2B and $255 on $2.3B.
If the stock runs without the estimate rising, I sell. A trailing stop only moves with price. This ceiling rises only when NTM FCF rises.

2. What I'm changing¶

The 10-K is a veto, not an edge. I also can't treat the 52% rally from $149 as proof the filing is clean. Social chatter cites 100-250% moves across software, so much of it is sector beta. Neither of us can read the filing from the price.
I'll underwrite ~25% exit growth, not 28%. Q3 to Q4 may include timing (your Data Center point, unverified). FY27 revenue of ~$8.2B at a 25-26% FCF margin gives your $2.0-2.2B. The thesis doesn't need 28%.
Your triggers are better than mine.
Pass: Rule of 40 at 52 or higher, growth at 25% or higher, and GAAP operating margin at 6% or higher.
Hold with no adds: Rule of 40 of 46-52, or GAAP margin of 0-6%.
Cut at least half: Rule of 40 below 46, growth below 24%, or GAAP margin below 0.
You are right that these fire after the gap. Only sizing protects through it.
No collar. I can't see the chain, and a $200 put sits inside the zone I'd expect after a middling print. Size is the hedge.
Pullbacks are routine here. The cited moves are −17% in three sessions in July, −9.4% in Sept, and −6% intraday on 10-16. So the rest of the position goes on limit orders.

3. What I still hold¶

a) Your table is a "value today" snapshot, and a holder lives on a different clock¶

Rolling each row forward 12 months, with my assumptions (clean case NTM FCF of ~$2.75B at 22-25x, so I give no credit for a re-rating):

Scenario	Your value today	My 12-month roll	vs. $227
Clean print	$217-243	$240-272	+6% to +20%
Middle	$175-200	$180-207	−21% to −9%
Miss	$135-150	$135-150 (no growth credit)	−41% to −34%

Your table also has no upside row. Q3 grew 31.7%. If Q1 is 29% growth with a 28% FCF margin and FY27 FCF margin guidance is 27% or higher, NTM FCF is ~$2.5B. At 25-28x that is $247-277. That is why I don't treat the clean row as a ceiling.

b) The pre-print starter is a coin flip, and I'll size it that way¶

Take a clean-print gap of +15% and a miss costing ~23% (your middle and miss rows weighted 70/30). Buying now beats waiting only if P(clean) is above ~61%. At a +20% gap the break-even is ~54%. I put clean at about 60%, no better, and I can't justify more from this data. That is break-even, so I'm cutting the starter from 1.5% to 1%. A −40% gap then costs ~0.4% of the portfolio.

c) Waiting has a price¶

In the prices cited, neither earlier gap was followed by a retrace to its pre-gap level. After the 05-01 gap from $68.59, the lowest price cited is $80.15. After 08-07, the Sept retrace stopped at $175.96 against a $149 pre-gap close. Your own pay-up plan buys "low-to-mid $240s," 6-8% above $227. That is a fair price for certainty, and you pay it to avoid a −9% to −41% miss. I'll pay for part of that certainty and take 1% of the exposure now.

d) What nobody here can resolve¶

SBC, organic growth, and the Q4 opex step are all 10-K questions. They aren't in either dataset. Reading the FY26 filing is the first action for whoever decides, before any order.

4. Final plan¶

Step	Action
Before anything	Read the FY26 10-K. Check the Q4 opex step for one-time items, SBC, acquired revenue, Data Center upfront revenue, buyback total and debt. If it fails, no position.
Pre-print	1% starter, unhedged. Earnings date unconfirmed, and the last bar may be partial.
Pullbacks	Limit buys of 1% each near $212 (10 EMA) and $200 (Bollinger midline). Cap pre-print exposure at 3%.
Print passes	Add up to 3% total while price is at or below 28x updated NTM FCF.
Print is middling	Hold the starter, no adds.
Print fails	Cut at least half. Cut to a token position if GAAP margin is below 0.
Valuation exit	Trim a third at 28x updated NTM FCF.
Thesis break	Weekly close below $160, or two straight quarters with Rule of 40 below 46.

Bottom line¶

TEAM is a business worth owning: ~85% gross margin, mid-20s growth, negligible capex, and a GAAP inflection that the 10-K may or may not confirm. At $226.83 the price is roughly fair for a clean print. Your table and mine both put the clean case at about today's price, rolled forward at +6% to +20%.

So my edge is in how I enter, not in whether the stock works. I take a 1% slice now, put limit orders where the stock has repeatedly pulled back, and add size only when the 10-K and the print supply the evidence. The remaining difference between us is 1% before the print versus 0% and a 6-8% higher entry after it, which is a small risk-budget decision rather than a disagreement about the business. Bull Analyst: # Bull Final for TEAM: The Starter Buys the Outcome a Limit Order Can't Reach

Your closing question is the right one, so I'll answer it first. Then I'll give back what you've earned and show where the numbers turn.

The short answer¶

The starter buys exposure in the clean-print state, which is where a resting bid at $200 doesn't fill. Your table credits the $200 rung with +12% as if it fills in every state. It fills when the stock falls, and the stock falls in the states where the thesis was wrong.

The two big prints in the dataset show the pattern:

05-01: the stock gapped from $68.59 to $88.88.
08-07: the stock gapped from $110.17 to $149.07.
Bids 12% below the pre-print close (about $60 and $97) filled in neither episode. The lowest prices cited afterward were $80.15 and $175.96.

That is n=2, and both started from depressed expectations, which is your point. It illustrates the mechanism and doesn't prove it.

What you've earned¶

The market-order starter is not an edge. On my inputs it is about −1%. Break-even P(clean) is ~61% against my 60%, and I can't defend a higher number from this data.
The $160 weekly line is not protection. $115.95 to $80.15 is −31% inside this recovery, and −31% from $227 is ~$157. I'm relabeling $160 as a re-underwrite alert and dropping it as a thesis-break. Sizing protects the portfolio. Fundamentals break the thesis.
Neither of us holds the 10-K, so neither plan can fire from this room. But the 10-K gate is in both plans, so it isn't an argument against the starter specifically.

Where the math doesn't hold¶

1. The 28x line is a trigger, not a ceiling¶

Your table treats $243–255 as the most the starter can earn. My rule is to trim a third at 28x of updated NTM FCF, and sell more if the stock runs without estimates rising. You've argued all debate that stops don't hold through gaps. Sells don't either.

If a clean print gaps to $261, the trimmed third sells at $261 (+15%), not at $243–255. The other two-thirds are re-underwritten against the new NTM. So the break-even at a +15% gap stays near 61%. The 77% and 66% figures come from capping the payoff at a line the gap would jump over.

2. The $200 rung's +12% assumes a fill that is anti-correlated with the good outcome¶

My fill assumptions below are illustrative, not data. I gave the limit order price improvement in the miss state.

	Clean (60%)	Middle (28%)	Miss (12%)
P(fill at $200)	35%	75%	100%
Return if filled	+28%	−3%	−19% (fills near $175 on a gap down; 12-month value $135–150)

Result: about +3% per unit of capital reserved, or +5.5% on the 54% of paths that fill. Your table says +12%.
Unfilled paths: 46% of paths end with no position, and 39 of those 46 points are clean-print paths.
Ranking: the limit still beats the market starter (about −1%, or about zero once you add an upside row your table lacks). I concede that.
Scale: the edge is 3–4 points on a 1% slice, or 3–4 basis points of portfolio. Taking it means being flat in the state where the thesis worked.

3. Your post-print buy has the same expected return¶

You'd pay up to 28x of updated NTM after a clean print. On $2.3B that is ~$255, and my clean-state roll of $240–272 gives −6% to +7% from there. Paying for certainty is legitimate, and I'd do it too. But then the difference between our plans is variance, not edge, and it is the 0.1–0.4% of portfolio you computed yourself.

Revised plan (moving toward you)¶

Step	Action
Gate	Read the 10-K first. If Q4 operating income is one-time or acquired revenue is above ~4 points, no position at any price.
Participation slice	0.5% at market, only after the gate passes. This is my cut from 1%.
Resting bids	0.5% near $212 (10 EMA), 1% near $200 (Bollinger midline), 1% at $188–195 (50-day, daily SuperTrend). Pre-print cap stays at 3%.
Print passes	Rule of 40 ≥ 52, growth ≥ 25%, GAAP operating margin ≥ 6%. Add up to 3% total while price is at or below 28x updated NTM FCF.
Print is middling	Hold, no adds.
Print fails	Cut at least half, and cut to a token position if GAAP operating margin is below 0.
Valuation	Trim a third at 28x updated NTM, filled at market, including through gaps.
Thesis break	Quarterly Rule of 40 below 46 for two straight quarters, or a 10-K showing Q4 operating income was one-time. A weekly close below $160 triggers a re-underwrite, not a stop.

Where this leaves us¶

What isn't in dispute, as I read your own concessions:

Business quality: gross margin of ~85% (Q4 ~86.5%, derived) and mid-20s growth on a $6.6B base.
Cash conversion: derived Q4 FCF of ~$474M at a ~27% margin, matching FY25's 27.1%.
Capex: about 0.5% of revenue.
Trend: weekly and monthly trends are up, with TD counts at −3 and −5 of 9.
Macro: recession odds are 8%, and October hike odds fell from ~30% to 12%.
Insider selling: the founders' plan sales stopped on 02-06.
Valuation: the clean case is worth roughly today's price, and more a year out.

The remaining gap is a 0.5% participation slice at roughly zero expected return, plus a $212 rung you dropped as marginal. The decision I won't make is letting the whole plan depend on a pullback, because a bid that fills mainly when the print disappoints isn't a way to own the business when it works.

The bull case is the franchise: re-accelerated growth, ~85% gross margins and a cash engine that held its Q4 margin. The price is full enough that I'd enter in stages and size for a −40% gap. I'd add on evidence and on weakness, and I'd keep a small position so that a clean print doesn't leave me with nothing.

Bear Researcher¶

Bear Analyst: # Bear Case for TEAM: A Great Business Priced as if the Cash Flow Statement Agreed With the Narrative

Your closing question¶

You ask for evidence that re-acceleration and margin expansion reverse. I don't need that. I need the evidence that margin expansion has not happened in cash terms, and that the price already assumes a lot more than continuation. Both are in your own data.

1. Growth was bought with margin, and the Rule of 40 didn't improve¶

You cite Rule of 40 at ~46 as "comfortably above the benchmark." Look at the trajectory (derived from the annual table):

FY	Growth	FCF margin	Sum
2024	23.3%	32.5%	55.8
2025	19.6%	27.1%	46.7
2026	26.0%	20.1%	46.1

FY26 growth rose 6.4 points and FCF margin fell 7.0 points. The score is flat, not improving. Over five years revenue grew 3.1x (FY21 $2,089M to $6,572M) while FCF grew 1.7x ($758M to $1,319M). That is a 25.7% revenue CAGR against an 11.7% FCF CAGR. GAAP operating margin is 0.2% today versus 6.7% in FY21, after tripling the business. The operating leverage the bull case assumes has not shown up in five years of data.

2. "Turned GAAP-positive" is one derived quarter you've already doubted¶

FY26 operating income was +$10M, a 0.2% margin. Through nine months it was –$200M, versus –$101M in the same period of FY25. Operating losses widened by about $99M through Q3 despite higher gross margin. The entire swing to positive is a derived Q4 of about +$210M, on revenue that was down sequentially ($1,787M to $1,766M), with opex falling about $260M. You conceded this needs the 10-K. I'd go further. The apparent CFO transition (Chuong's 297K-share grant on 4/2, Binz gone after February) puts a new finance chief at the start of the quarter with the unexplained swing. I'm not alleging anything. But until someone explains that quarter, it shouldn't be capitalized at 34x.

That 34x is on non-GAAP earnings, and TTM GAAP EPS is –$0.21. Free cash flow of $1.32B against GAAP operating income of $10M leaves a gap of roughly $1.3B. SBC isn't broken out in my data, but in application software that gap is largely stock comp (inference). FCF doesn't charge for it, and the buyback has to absorb it.

3. The "28% FCF growth" quarter is just revenue growth¶

Derived Q4 FCF was $474M on $1,766M of revenue, a 26.8% margin. Q4 FY25 was $375M on $1,384M, a 27.1% margin. Cash flow grew in line with revenue and the margin didn't expand. That is stabilization, not a break in the compression narrative. It also implies the first nine months of FY26 ran at about a 17.6% FCF margin ($845M on $4,806M), versus 27.1% a year earlier. Nine-month FCF fell about 19% while revenue grew about 25%. One good quarter doesn't make a trend, and you said yourself that Q1 FY27 must confirm it. The stock is already priced as if it has.

4. The exit rate is softer than the headline¶

Q4 revenue fell 1.2% sequentially after Q3 jumped 12.7%. If Q1 FY27 merely matches Q4's $1,766M, YoY growth is 23.2%. Holding 28% requires about $1,834M, or +3.8% sequentially. Comps also get harder from here, since Q3 FY26 is now the high-water mark. The re-acceleration is also entangled with large investing outflows (–$1,144M in the December quarter, –$807M for the year), "consistent with acquisition activity" per the fundamentals report. If any of the +31.7% was inorganic, "rare re-acceleration at scale" is overstated. I can't separate it from this data, and neither can you.

5. Balance sheet: "typical of software" doesn't explain the change¶

The current ratio was 1.18 in FY24 and 1.22 in FY25. It is 0.78 now. Current assets fell 28% and current liabilities rose 12% in a single year. Cash is down 51% to $1.24B against roughly $1.2B of debt (inferred from D/E of 1.16x). That's about zero net cash. If the buyback was as large as you infer, it bought stock at $60 to $120. The buyer that supported the shares at the lows now has less cash, and each dollar retires far fewer shares at $227.

6. What the price requires¶

Market cap is ~$57.4B, so the FCF yield is 2.3% (2.9% on the feed's higher FCF figure). Suppose you want 10% a year for five years. That means ~$92B in 2031. At a still-generous 25 to 30x FCF exit multiple, FCF must reach $3.1B to $3.7B, an 18% to 23% CAGR. The five-year record is 11.7%. These are my assumptions and the math ignores buybacks, but it frames the bet. The market is paying for FCF growth the company has not yet delivered. The "discount to 3-year average sales multiple" line on StockTwits (7.1x vs 9.8x) predates the last leg up. At 8.7x there's little cushion left. And the stock is up ~52% since the August 7 gap to ~$149, with no new financial statements.

7. The AI argument uses a lagging indicator¶

You say re-acceleration after the drawdown contradicts "AI kills seat-based SaaS." But reported revenue reflects contracts signed and seats provisioned in prior periods. The disruption thesis is about renewals, seat counts and net expansion over years, and one strong fiscal year can't refute it. The debate is live, with "model moats" headlines and a 9% AI-bubble-burst probability that rose 3 points this week. Zoom appearing among the biggest value losers since 2021 is a reminder of what happens to collaboration names after a re-rating.

You also concede that the rebound is sector-wide (OKTA, CRWD, TWLO and others up 100% to 250%). If so, a meaningful part of TEAM's move is software beta, and it can reverse on sector news with no TEAM-specific cause.

8. Targets, positioning and the technicals you left out¶

The targets you cite say "fully valued." KeyCorp at $235 is +3.6% from here, Barclays at $222 is –2.1%, and Mizuho at $235 is +3.6%. The consensus of $198.59 is about 12% below the price. Targets that chase price are lagging, not a catalyst.
The setup changed. The last two gaps (+29.6% and +35.3%) came from $68 and $110, when expectations were depressed. The next print faces a stock up 26.5% in 15 sessions, with retail talking about $260 to $300 and a few already worried about a return to $150. The asymmetry has flipped.
MACD is below its 9/21 level (10.54 vs 11.96) while price is higher. You didn't mention it. The October leg ran on 1.4M to 3.7M shares a day versus 20M+ on the gap days, and the 10/16 bar fell 4.3% intraday with a 9% range.
Your risk lines don't hold through the event. Your stops are the 10 EMA at $212 (only 6.5% away) and the $195.85 daily SuperTrend. You admit ATR understates gap risk, and a gap goes straight through a stop. Your thesis break is a weekly close at $160, a 29% drawdown. "Size sensibly" reduces to "don't be heavily exposed into the print," which is my point.
Macro offers no tailwind. The market prices "no cuts in 2026" at 97%, a 12% hike tail, and only 24% odds of a no-dissent FOMC on 10/29. That's a long-duration multiple with no help from rates, probably in the same week as earnings (date unconfirmed).

Where you're right, and what would change my mind¶

Revenue acceleration is real, gross margin at ~85% is excellent, capex is negligible, and this is a high-quality franchise. My objection is to the price paid for a margin story the cash flow statement hasn't confirmed.

I'd change my view on any of these: 1. The 10-K shows Q4 operating income is recurring, not one-time. 2. Q1 FY27 shows FCF margin expanding year on year, not just matching. 3. Organic growth is disclosed and holds at ~25% or better. 4. A price that offers a margin of safety. That means a pullback toward the $188 50-day average or the $200 Bollinger midline, not +26.5% in 15 sessions.

Bottom line¶

At $226.83 you're paying 8.7x sales, ~2.3% FCF yield and a 34x non-GAAP multiple for a company with flat Rule of 40, FCF down 7% in FY26, a GAAP "turn" resting on one unexplained quarter, and a thinner balance sheet. The next print has to beat a stock priced for perfection, and the sell-side targets you cite imply roughly no upside. I would not initiate here. I'd trim into strength if holding, and revisit after the Q1 FY27 numbers or a pullback toward the mid-$190s to $200. Bear Analyst: # Bear Rebuttal for TEAM: Your "Exit Rate" Is One Residual Quarter, and Several of Your Fixes Cut the Other Way

You've conceded a lot: FCF fell 7%, SBC is the real gap to GAAP, stops don't hold through a gap, price is ahead of verified data, and targets show almost no upside. I'll concede in return that the CFO point was inference I don't need, and that Q4's Rule of 40 (~54) is a fair number for that one quarter. Below are the places where your rebuttal doesn't hold.

1. The "seasonal adjustment" isn't a seasonal adjustment¶

In FY25, Q4 FCF was $375M on $1,384M of revenue, a 27.1% margin. The full-year FY25 margin was also 27.1%, and the nine-month margin was 27.15% ($1,040M on $3,831M) (all derived). There was no seasonality to adjust for. Q4's share of FCF (26.5%) equals its share of revenue (26.5%).

So "$1.79B seasonally adjusted" is really "what FCF would be if the whole year ran at Q4's margin." The nine-month FY26 margin was 17.6%, a 9-point gap inside one year. Two readings fit that gap, and the data can't separate them:

Yours: the nine months were depressed by one-offs.
Mine: Q4 was boosted by timing or a collection pull-forward.

Q4 is a residual (annual minus nine months), and the feed and the SEC figures already disagree by $336M on annual FCF. Q4 was 35.9% of FY26 FCF versus 26.5% last year. Your own weights applied to the nine months give about $1.15B ($845M ÷ 0.735). Applied to Q4 they give $1.79B. Choosing the high one is the argument, not a derivation. Your hurdle table's $1.79B base hasn't been delivered.

2. Your growth scenario halves growth but keeps the multiple¶

Your path has revenue growing 12–15%, FCF margin returning to 27.5%, and a 25–30x exit multiple.

The margin assumption reverses the trend. The 27.5% average includes FY24's 32.5%, and FCF margin has fallen two years running.
The multiple doesn't match the growth. A 12–15% grower is not a 25–30x FCF business, and that is before charging SBC. My judgment is 20–22x. On your $3.2–3.6B, 20x gives $64–72B, or about 2–5% a year from $57.4B. You only clear 10% at 30x.

3. The opex table doesn't say what you say it does¶

I ran year-over-year opex growth by quarter (derived, using FY25 quarterly gross margins):

	Q1	Q2	Q3	Q4	FY
Opex YoY	+27%	+25%	+38%	+12%	+25.1%
Revenue YoY	+20.6%	+23.3%	+31.7%	+27.6%	+26.0%

Annual leverage is small. Opex/revenue went from 85.3% to 84.7%. Of the 2.7-point rise in GAAP operating margin, about 2.0 points is gross margin. Nine-month opex grew about 30% against 25% revenue growth. The "very strong leverage" appears only if you start the clock at Q1 and end at Q4: +3.5% opex on +23% revenue. Last year's Q1→Q4 was +17.8% opex on +16.5% revenue.
Your Q3-charge diagnosis doesn't explain Q4. Remove your $182M Q3 excess and normalized Q3 is about $1,398M, flat with Q2. Q4 at $1,316M is still $82M below that, and $82M below Q2 on revenue that is 11% higher. A company still adding people doesn't normally cut absolute opex. Possible mechanisms are SBC forfeiture reversals, accrual releases and contingent-consideration remeasurement. That list is speculation on my part, and it is the reason someone should read the filing.
The filing probably already exists. FY26 annual figures are in our dataset, so the Q4 release is out. The 10-K normally follows within weeks (my background recollection, so verify). You wrote that "the print and the 10-K will deliver" the answers on Q4 recurrence and organic growth. That is a diligence task we can do today, not a catalyst.

4. Your inorganic arithmetic points the other way¶

The multiple isn't "very cheap." Your $270M of annualized revenue against a $1.14B outflow is about 4.2x revenue. At 5–10x revenue (my assumption), $1.14B buys $115–230M of ARR. That is 2–4 points of YoY growth in a quarter, against a 7-point acceleration from Q1's 20.6% to Q4's 27.6%. That assumes the whole outflow was M&A, which neither of us knows.
H2 vs. H1 can't separate the two. An H2 acceleration from 22.0% to 29.6% is also exactly the shape acquired revenue would produce if the deals closed in the December quarter.
Q1 FY27 can't answer the organic question. If those deals closed in the December quarter, the Q1 FY26 comp contains none of that revenue, so Q1 FY27 growth carries it in full. The first clean organic read is around Q3 FY27. Your closing claim that the print is the only evidence that separates us is therefore wrong for organic growth.
You switch yardsticks. You use Q4 alone where it flatters (cash, opex) and H1/H2 smoothing where it doesn't (revenue). On Q4 alone, growth slowed 4 points from Q3 and revenue fell $21M after a +12.7% jump.

5. Gross margin is not a demand indicator¶

Seat compression and weak net expansion show up in seats, NRR, pricing and cRPO. Gross margin tracks hosting efficiency, mix and scale, so it rises as revenue grows against a fixed cost base. It can keep rising while seat counts erode. Neither dataset has the real tests. I'll grant Zoom is an imperfect analogue, since I used it only as a read-through.

6. Two technical points you got backwards or flattered¶

MACD scaling cuts against you. Normalized by price, MACD is 4.6% now versus 6.1% on 09-21. Dividing by price makes the divergence larger, not smaller. The slow EMA catching up to the August gap is the mechanism, and it means October's thrust is weaker than September's, on lighter volume. It's a minor signal and I wouldn't trade it alone, but your rebuttal had the direction wrong.
The valuation comparison is generous. The 3-year average came with a ~27.8% FCF margin (FY23–25). At 9.8x sales that is about 35x FCF. Today's 8.7x on a 20.1% margin is about 43x. The "11% below average" on sales is a roughly 23% premium on FCF. The 7.1x vs. 9.8x figures are unverified.

7. Your triggers can't catch the loss, and waiting has a smaller cost than you think¶

The triggers are too loose. "Growth below ~23%" equals flat sequential revenue. A print of 24% growth with a 22% FCF margin trips none of your four triggers, yet I'd expect it to gap hard, because the stock is priced for 27/27 or better.
The earlier gaps started from low prices. The +30% gaps came from $68 and $110. The next print starts above the $198.59 consensus target, after a 52% run since the August 7 close of $149.07.
Break-even odds are high. This is a binary simplification. Upside to retail's $260 is +14.6%, and a retrace to $149 is –34.3%. The good-print probability needed to break even is about 70%. Retail's $300 lowers that to about 52%. Both figures assume the market pays for a clean print and punishes a miss symmetrically with the August gap.
Sizing at 3% is fine. It is also my position. We agree on sizing, and what's left is whether to start before the print and at this price.

Your question: is 32x exit-rate FCF still a price I'd refuse if Q1 shows 27% growth and 27% FCF margin?¶

Yes, and here is my number. Grant the bull case in full, with a clean 10-K, organic growth and recurring Q4 operating income. FY27E revenue of about $8.2–8.3B at a 25–27% FCF margin gives ~$2.0–2.2B of FCF. At $57.4B that is already 26–29x forward, not 32x of a base that hasn't been delivered. For a ~25% grower whose FCF doesn't charge SBC, I'd pay 22–25x. That is ~$46–52B, or ~$185–205 a share (253M shares). It brackets the 50-day average ($188) and the Bollinger midline ($200), which is close to the staging zone you proposed ($200–212).

So part of our disagreement is the multiple, and we're close on a price. The other part is evidence quality: Q4 is a residual in two statements, M&A isn't separated, and the opex step is unexplained.

Bottom line¶

At $226.83 the market is paying today for the 27/27 print, a clean 10-K and organic growth, with nothing left over for a miss. I would not initiate here. If I held it, I'd trim or collar into the print. I'd revisit at $185–205, or after the 10-K shows recurring Q4 operating income and organic growth near 25%.

My question back: name one print outcome short of a collapse that would make you sell. If 24% growth and a 22% FCF margin doesn't, your thesis can't be falsified at this price by anything the stock can't already gap through. Bear Analyst: # Bear Rebuttal for TEAM: We Agree on the Business. The Price Is What's Left.

You answered the falsifiability question properly, and your corrections were generous. I'll concede a few things in return, then cover what still doesn't hold.

What I'm conceding¶

The M&A worst case doesn't erase the acceleration. On my own 5-10x assumption, Q4 organic growth is still 23.4-25.5% against 20.6% in Q1. I leaned too hard on "bought growth." Early-stage targets usually sell at higher revenue multiples than 5-10x, which would mean less acquired revenue.
Your NTM weighting is correct. Three-quarters of FY27 plus one-quarter of FY28 is the right frame.
"24/22, cut half" is a real trigger. It is what I asked for.

1. A passing 10-K is a veto, not an edge¶

You inferred the 08-07 gap was the FQ4 report. I agree, and I'd add that Atlassian usually files the 10-K within weeks of that report (my recollection, unverified). If so, the filing has been public for about two months, and the stock is up 52% since $149.07.

The 10-K gate stops you from initiating on a bad filing, and that is useful. But if the filing is clean, you've only confirmed what the extra $78 a share already paid for. The only unpriced information left is the Q1 FY27 print. Also, neither of us has read the filing, so we are putting thresholds on a document nobody in this debate holds.

2. Your question: yes, my range is evidence-contingent¶

If the 10-K shows Q4 operating income recurring and acquired revenue under 2 points, I stop applying a 22-25x multiple and move to 25-28x. Recurring operating income is the item that matters. It would mean SBC leverage is real and FCF is closer to owner earnings. Scenario values below use my multiples and the NTM method you endorsed. They are values today, not 12-month targets.

Scenario	NTM FCF	Multiple	Value/share	vs. $227
Clean 10-K, Q1 near 27/27	~$2.2B	25-28x	$217-243	–4% to +7%
Growth ~24-25%, FCF margin ~23-24%	~$2.0B	22-25x	$175-200	–23% to –12%
24/22 print, or Q4 was timing	~$1.7B	20-22x	$135-150	–34% to –41%

(253M shares. Carry over a year helps every row, but doesn't change the shape.)

The good case is roughly today's price and the other two are 12-41% below it. A clean 10-K moves my fair value up to where the stock already trades. That is not a margin of safety. Even if you assign 60% to the first row, the weighted gap to $227 is negative.

Some things the 10-K can't fix. FCF of $1.32B against $10M of GAAP operating income leaves a gap of about $1.3B, which is mostly SBC in this industry (inference). Until that gap narrows, the cash flow statement doesn't charge for what GAAP does.

3. "Your entry never shows up": this dataset says it did¶

June leg: $96.43 on 07-20 fell to $80.15 on 07-23, down 17% in three sessions.
After the 08-07 gap: $194.17 on 08-31 fell to $175.96 on 09-29, down 9.4%. That was well inside the zone you call fair.
Last week: The 10-16 bar ran from $217.12 to a $204.00 low.
Volatility: ATR is 4.1% of price, so a 10-17% retrace in a month is routine.

On a clean print, $250 is 28.7x your own NTM FCF ($63.25B ÷ $2.2B). That is about four turns above the top of your 22-25x range. You wouldn't be missing your entry there. You'd be declining to pay.

4. The collar and the triggers¶

Collar: A $200/$260 collar caps the upside at the outcome you say you'd regret missing. The $200 put sits inside the $185-205 zone you assign to a 24/22 print. Your base case ($175-200) lands at or below the put, so the collar turns it into the maximum loss. The 45% break-even also ignores premium. I can't see the chain, but a 12%-OTM put into earnings on a 4%-ATR name is not cheap, and skew means the call won't fund it. If 24/22 lands at $185-205 and you'd buy there, what you need is a limit order, not a hedge.
The Rule of 40 trigger is still loose. Q4 was 54 and the price needs about that. A print of 25% growth and 26% FCF margin scores 51 and passes your <50 trigger. It would also be the second straight growth deceleration (31.7% → 27.6% → 25%). I'd set the trigger at 52.
The GAAP trigger needs a margin. "≤0" lets a 1% operating margin through, which still kills the "12% recurring" claim. I'd set it at under 6%.
Timing: Your triggers fire after the gap. Cutting half after a 25% drop is risk management on what's left, not a way to avoid the loss.

5. What the M&A worst case still leaves¶

Under any acquired-revenue assumption, organic growth fell about 4 points from Q3 to Q4. Organic revenue also fell at least $21M sequentially, since acquired revenue wouldn't have shrunk. The acceleration ran Q1 to Q3: 20.6%, 23.3%, 31.7%, then 27.6%.

The 10-K should say whether Q3 included upfront-recognized Data Center license revenue. That is my recollection of how Atlassian books term licenses, unverified. If it did, the Q3 spike and Q4 dip are timing, and the exit rate is nearer 25% than 28%.

6. What would make me pay up¶

Here is the symmetric answer to your question. I'd buy at $227 or higher if all of these hold:

The 10-K is clean.
Q1 FY27 shows 27% or better growth (about $1.82B).
Q1 FCF margin is 26% or better.
GAAP operating margin is 8% or better.
FY27 FCF margin guidance is 25% or better.

I'd then underwrite 25-28x and own it in the low-to-mid $240s. I'd be buying after the evidence, and I accept that I would miss the first leg.

Bottom line¶

We agree on the business: about 85% gross margin, mid-20s growth and negligible capex. We agree the position should be small. We now agree your best case is roughly today's price, because your own table puts it 3-16% above fair value. What's left is whether to own 1.5% hedged before the print or 0% until it arrives. I'd wait. The filing is probably already priced, the pullbacks have recurred in this data, and a clean-print gap to $250 would be outside your own multiple.

My question back: if a clean print gaps the stock to $250, you'd be holding at 28.7x NTM FCF, outside your own 22-25x range. Do you sell the starter into the gap, or does your range move with the price? If it moves, it isn't a valuation range, it's a trailing stop. Bear Analyst: # Bear Final for TEAM: We Agree on the Business and the Fair Value. What's Left Is a $227 Starter With No Edge

We now agree that FY26 FCF fell 7%, SBC is the real gap to GAAP, neither of us has read the 10-K, and sizing is the only protection through a gap. Your closing also improved the debate in three places, so I'll concede those before showing where the numbers turn against the starter.

What I'm conceding¶

The forward clock is the right frame. A holder lives on a 12-month horizon, not on my "value today" snapshot.
A multiple tied to NTM inputs is a valuation rule, not a trailing stop. I withdraw that charge. Trimming at 28x of updated NTM FCF is coherent.
No collar is right. Neither of us can see the chain, and a $200 put sits inside the zone a middling print produces.
Your upside row is fair. A 29/28 print supports $247–277.
Waiting for a post-gap pullback is not guaranteed. Neither gap in the data retraced to its pre-gap level, so I'm not relying on that.

1. Your sell line caps the starter's payoff below your break-even¶

Your break-even (~61% at a +15% gap) assumes the clean print gaps to about $261. Your own rule says to trim at 28x updated NTM FCF.

NTM FCF after print	25x	28x (your trim line)	vs. $226.83
$2.2B	$217	$243	–4% to +7%
$2.3B	$227	$255	0% to +12%
$2.5B (your upside row)	$247	$277	+9% to +22%

A +15% gap ($261) is about 28.7x on $2.3B and 30x on $2.2B, above your sell line in both cases. Against a ~23% cost in the bad states, the break-even P(clean) is:

~77% at +7%
~66% at +12%
~51% at +22%

At your 60%, the starter works only if the print lands in the upside row, meaning the stock gaps past the multiple you've committed to selling. I don't read that as an edge.

2. Expected return by entry price, on your inputs¶

I used your 12-month roll values ($240–272 clean, $180–207 middle, $135–150 miss), your 60% clean probability, and your 70/30 split of the remainder (28% middle, 12% miss). Midpoints are in parentheses.

Entry	Clean (60%)	Middle (28%)	Miss (12%)	Weighted
$227	+6% to +20% (+13%)	–21% to –9% (–15%)	–41% to –34% (–37%)	≈ –1%
$212	+13% to +28% (+21%)	–15% to –2% (–9%)	–36% to –29% (–33%)	≈ +6%
$200	+20% to +36% (+28%)	–10% to +4% (–3%)	–33% to –25% (–29%)	≈ +12%

These figures are undiscounted. Against a ~10% hurdle, only the $200 rung clears. The $212 rung is marginal and $227 is negative. Your clean row also needs ~$2.75B of NTM FCF a year from now, which is 25% growth sustained against harder comps.

This is why I agree with your ladder and not your market-order tranche. Your analysis already identifies the order that pays, a limit at $200. The $227 slice is the piece that doesn't.

3. At 1%, the starter is a hedge against regret¶

At your sell line, the best case on 1% of the portfolio is +0.07% to +0.12%. The middle and miss cases cost about –0.1% to –0.4%. You've sized the position so that being right adds almost nothing and being wrong costs several times as much. That is a way to feel involved, not an investment decision. It also doesn't match your summary of the difference as "1% vs. 0%". The pre-print cap in your table is 3%.

4. Your thesis-break line sits inside normal drawdown¶

The technical report's prices show 115.95 on 06-01 and 80.15 on 07-23. That is at least –31% (derived) inside this same recovery, not the –17% three-session slice you cited as routine. Apply –31% to $227 and you get ~$157, through your weekly $160 break line.

Either that stop would have sold you the low of a drawdown that reversed, or it isn't a stop at all. The only real downside protection in your plan is sizing and entry price, which is where I've put the weight.

5. The plan returns "no order" on the evidence we hold¶

Your first step is to read the 10-K, and if it fails there's no position. You've also agreed the filing can veto but can't add edge, and neither of us holds it. On what is actually in this debate, your plan's output is "no order yet." The earnings date is unconfirmed too, so "pre-print" could mean days or weeks. A starter bought blind on both counts is the least informed version of your own trade.

Where I land¶

Step	Action
Now at $227	0%.
10-K	Read it first. If Q4 operating income is one-time or acquired revenue is above ~4 points, no position at any of these prices.
Pullbacks	Start 1% at or below ~$205, add toward $188–200 (the 50-day and Bollinger midline). This is your ladder, with the $212 rung dropped as marginal.
Post-print	Pay up to 28x updated NTM FCF if Q1 shows 27%+ growth, a 26%+ FCF margin and 8%+ GAAP operating margin, and FY27 FCF margin guidance is 25%+.
Middling print	Sit out.

Bottom line¶

We agree on the business: ~85% gross margin, mid-20s growth and negligible capex. We agree the clean case is worth roughly today's price, with your own 28x line capping it at +7% to +12% unless estimates rise. And we agree the position should be small. The only disagreement left is a $227 market-order tranche whose expected 12-month return, on your own numbers, is about –1% against a risk-free hurdle that is higher. Pullbacks have been routine in this data, with ATR at 4.1%, beta at 1.23, a sector-wide rally and no help from rates. If you want the exposure, your $200 limit gets paid and the $227 tranche doesn't.

My question back: your table gives about +12% for the $200 rung and about –1% for the $227 starter. What does the starter buy that the limit order doesn't, other than insurance against pullbacks that your own data says keep happening? Bear Analyst: # Bear Final for TEAM: The Corrected Table Flattens Every Way of Owning It at $227

Your correction of my ladder table is right. I'll take that first, then show what your inputs say about the starter.

What I'm conceding¶

I assumed a 100% fill. My +12% for the $200 rung treated it as filling in every state. It doesn't, and the unfilled paths cluster in the clean-print state. Your +3% per unit reserved (+5.5% on filled paths) has the right shape. The 35/75/100% fill odds are your illustrations, not data.
The one-third trim isn't a cap. My 77%, 66% and 51% break-evens treated 28x as a ceiling on the whole starter. At a +15% gap, break-even is about 61%, as you say.
The two bids didn't fill. Bids 12% below the pre-print close ($60 and $97) filled in neither episode. I'm not relying on a post-gap retrace.
$160 is a re-underwrite alert, not a stop.

1. What the starter buys¶

It buys the clean-print gap. Using your payoff midpoints (+13% clean, −15% middle, −37.5% miss) and your 70/30 split of the non-clean states, expected 12-month return is about 34.75 × P(clean) − 21.75. This is my arithmetic, undiscounted:

P(clean)	Starter expected return
60%	≈ −1%
70%	≈ +2.6%
80%	≈ +6%
~91%	≈ +10% (my hurdle)

You said you can't defend more than 60% from this data. The problem is the payoff shape: the upside is capped by the multiple at which you start selling, while the downside is open. Each 10 points of P(clean) adds only about 3.5 points of return.

The payoff is also front-loaded. A +15% gap lands at about $261, which is 28.7x on $2.3B of NTM FCF. That is above your trim line and above the $256 midpoint of your own 12-month clean range. After the gap, your roll implies a forward return on the rest of about −8% to +4%. So in the state where it works, the slice "owns the business" for roughly one session.

Way to own it	Expected return on your inputs	Left tail
Market slice at $227	≈ −1% to 0%	−37% miss state
$200 limit	+3% per unit reserved (+5.5% if filled)	−19% (fills on a gap-down)
Post-print buy at 28x (~$255)	−6% to +7%, about 0%	No miss state

Every expression is worth roughly cash. You called the difference "variance, not edge." I agree, and that is why I prefer the version without a miss state.

This also exposes a flaw in my own plan. My post-print ceiling of 28x is too generous. To earn 10% on your clean midpoint of $256, I'd need to enter at or below about $233, which is about 25–26x on $2.3B. I'm revising my ceiling to 25–26x unless the print also lifts FY28 estimates. Your plan adds up to 28x and trims a third at 28x, so you would buy and sell at the same line.

3. At 0.5%, the slice is about regret, not return¶

Size: +6 to +8 bps in the clean state, about −19 bps in the miss state.
Inconsistency: Your second rebuttal said the daily TD-9, RSI at 70.03 and a possibly partial final bar "all support not chasing." A market order into those is chasing.
Adverse selection is real for deep bids, less so for shallow ones. Two ATR below the close is $208.35, and the 10-16 bar already printed $204.00 intraday on a −4.3% close. A fill there is ordinary volatility, not evidence the thesis has broken. So the first rung belongs near $205–208, sized to ATR rather than to a valuation level. That answers your objection without a market order.

4. What the "not in dispute" list omits¶

Macro: The list leaves out "no cuts in 2026" at 97%, the 10/29 FOMC with only 24% odds of no dissent, and AI-bubble odds up 3 points to 9%. The earnings date is also unconfirmed, so "pre-print" could mean days.
Open items: Q4 FCF is a residual from two statements that disagree by $336M on annual FCF. The roughly $1.3B gap between FCF and GAAP operating income is unexplained, and organic growth isn't separated. Your own gate depends on all three.

Where the plans stand¶

	Bull (revised)	Bear
Now	0.5% at market after the gate passes	0%
Pullbacks	0.5% at $212, 1% at $200, 1% at $188–195	1% at ≤$205–208, add toward $188–200
Post-print	Add up to 28x, trim a third at 28x	Add up to 25–26x if 27%+ growth, 26%+ FCF margin, 8%+ GAAP margin
Middling print	Hold, no adds	Sit out

The disagreement is now about 0.5% of a portfolio, which is the market slice. The business isn't in dispute: about 85% gross margin, mid-20s growth, and negligible capex.

Bottom line¶

At $226.83 the stock is priced for the clean case. On your payoffs that case is worth about today's price, the middle case is −15%, and the miss case is −37%. I wouldn't buy at market. I'd rest shallow bids at $205–208 and below, and let the 10-K and the Q1 FY27 print supply the edge. If I held it, I'd trim into the print.

My question back: you can't defend P(clean) above 60%, and at 60% every version of this trade is worth about cash. What in your plan raises that number before the print, other than a 10-K the market has probably already read?

Research Manager¶

Recommendation: Underweight

Rationale: This debate converged more than most, so the call is about price and event risk, not business quality. Both sides end up agreeing the franchise is strong, and neither wants a full position at $226.83. The bear won the arguments that set the entry, and that tips me to a modest trim rather than a Hold.

The bull's case on the business is real: - Revenue re-accelerated to $6.57B (+26%). H1 grew 22.0% and H2 grew 29.6%. - Even if the entire $1.14B investing outflow was M&A at 5-10x revenue, Q4 organic growth is still about 23-25%, against 20.6% in Q1 FY26. - Gross margin is about 85%, capex is about 0.5% of revenue, and FCF is about $1.3B. - Weekly and monthly trends are intact, the founders' plan selling stopped on 02-06, and recession odds are 8%.

The bull also made one point I'm keeping. A resting bid fills mostly in the states where the thesis failed. Neither of the two post-gap episodes in the data retraced to its pre-print level. That is why this is Underweight rather than Sell: you want some exposure left if the print is clean.

The bear dismantled the case for paying today's price: - The 'exit rate' is one residual quarter. FY25 had no FCF seasonality (27.1% margin in both the first nine months and Q4). FY26 ran 17.6% for nine months, then 26.8% in a derived Q4. The bull withdrew the $1.79B FCF base. - Operating leverage was small. Full-year opex/revenue only moved from 85.3% to 84.7%. The Q4 GAAP turn rests on an unexplained opex drop, and the bull conceded it isn't a run-rate. - Valuation is full on cash. FCF yield is 2.3%, about 43x TTM FCF and about 26x NTM even in the clean case. The ~$1.3B gap to GAAP operating income is likely mostly SBC, which FCF doesn't charge. - Expected return is about cash, with a fat left tail. Using the bull's own payoffs and his 60% clean-print probability, a market buy returns about -1% over 12 months. The clean case is +13%, the middle case -15% and the miss case -37%. The upside is effectively capped near the 28x multiple where the bull himself would trim. - Sell-side targets offer little. Most targets cluster at $222-235, and the cited consensus of $198.59 is 12% below the price. - The near-term setup is stretched into a binary event. The stock is up 52% since the August 7 gap with no new statements. The daily TD-9 and RSI of 70 are flashing, MACD is weakening relative to price, and October volume was light. Beta is 1.23 in a sector-wide rally, rates offer no help, and the earnings date is unconfirmed. - The open questions are all unresolved. SBC, organic growth and the Q4 opex step all depend on a 10-K nobody in this debate has read.

Net: the business case is right, but the price already pays for the clean outcome, and the risk is skewed to the downside into the print. Trim to a reduced core, then rebuild on evidence or at better prices.

Strategic Actions: Sizing is relative to a standard full allocation (SA).

1) Pre-execution checks. - Verify the live price, since the last bar may be partial. - Confirm the Q1 FY27 earnings date. - Read the FY26 10-K for: the cause of the Q4 opex drop (one-time credits or recurring), SBC, acquired revenue, any upfront Data Center license revenue in Q3, buyback size and debt. - If Q4 operating income was mostly one-time, or acquired revenue exceeds about 4 points of growth, cut to a token or zero position. Make no adds at any price.

2) If you hold at or above SA: trim to about 50% of SA before the print. - Scale out over several sessions, using strength toward $230-235 (the KeyCorp and Mizuho targets). - Do not trim on weakness below about $212. - Keep the remaining half so a clean print isn't missed.

3) If you hold no position: do not buy at market. Rest limit bids, capping pre-print exposure at 50% of SA: - About 15-20% of SA at $205-208 (about 2 ATR, near the 10-16 low). - About 15-20% of SA at $195-200 (Bollinger midline and daily SuperTrend at $195.85). - About 15% of SA at about $188 (50-day average).

4) Size for the gap, not a stop. - Assume a 35-40% gap-down is possible. ATR understates it, and stops won't fill through it. - Treat a weekly close below $160 as a re-underwrite alert, not an automatic stop. - No options structures are recommended. Neither side could see the options chain.

5) Post-print rules for Q1 FY27. - Pass: quarterly Rule of 40 at 52 or above, revenue growth at 25% or above (about $1.79B, ideally 27%+), FCF margin at 26% or above, GAAP operating margin at 6% or above (8%+ ideal), and FY27 FCF margin guidance at 25% or above. Rebuild toward full SA, but only while price is at or below about 26x updated NTM FCF. That is roughly $226-236 a share on $2.2-2.3B of NTM FCF, with each turn of multiple worth about $9 a share. Above 28x updated NTM FCF, trim a third. - Middling: Rule of 40 of 46-52, or GAAP operating margin of 0-6%. Hold the reduced position and make no adds. - Fail: Rule of 40 below 46, growth below 24%, or GAAP operating margin below 0. Cut to a token position or exit. Two straight quarters with Rule of 40 below 46 is a thesis break.

6) Missing data that should feed back into this plan: - The 10-K itself. - SBC, NRR, seat counts and cRPO. - The earnings date. - The options chain. - Reconciliation of the $336M annual FCF discrepancy between the data feed and the SEC figures.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan's Underweight maps to a modest trim, not a full exit. The business case is strong, but at 226.83 the price already pays for a clean print. Using the bull's own payoffs, the 12-month expected return is about -1%, with a fat left tail (-15% middle case, -37% miss case) and the earnings date unconfirmed. The technicals show a strong trend that is stretched on the daily timeframe: RSI 70.03, a completed daily TD-9, z-score 1.88, %B about 0.97, price 6.9% above the 10 EMA, and light October volume. The weekly and monthly trends are intact, so keep about half of a standard allocation (SA) rather than exit. Gap risk matters more than a stop here, since ATR (9.24) understates the +35% August gap. The last bar may be partial, and the 10-K, SBC and earnings date are all missing, so verify the live price and read the 10-K before executing.

Entry Price: 206.0

Stop Loss: 160.05

Position Sizing: Relative to a standard full allocation (SA). If at or above SA, trim to about 50% of SA before the print, scaling out over several sessions into strength toward 230-235 and not selling below about 212. If flat, do not buy at market. Rest limit bids totalling at most 50% of SA: 15-20% at 205-208 (the 206.0 entry shown is a rebuild level, about 2 ATR below the close), 15-20% at 195-200 (Bollinger midline and daily SuperTrend 195.85), and about 15% near 188 (50 SMA). Size for a 35-40% gap-down, since stops will not fill through it. The 160.05 weekly SuperTrend level is a re-underwrite alert on a weekly close below it, not a hard stop. If the 10-K shows the Q4 opex drop was one-time or acquired revenue exceeds about 4 points of growth, cut to a token or zero position and make no adds.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Since neither of you has spoken yet, I'll open and then answer the arguments I expect to hear.

First, what "aggressive" means here. It doesn't mean holding a stock because it's going up. It means taking asymmetric bets and being willing to act against the crowd when the payoff is lopsided. On TEAM, the lopsided part is the left tail. The trader's own scenario math, using the bull's payoffs, gives a 12-month expected return of about -1%, with a -15% middle case and a -37% miss case. At 226.83 the stock is up roughly 297% from the April closing low, and we're being asked to pay full price for a clean print. When I'm being paid nothing for the risk, the aggressive move is to monetize part of a 4x and keep dry powder to buy the next dislocation harder.

Notice that this is not a full exit. It's a trim to about half a standard allocation, scaled out into strength toward 230-235, with resting bids at 205-208, 195-200 and 188. I keep half the upside if this runs to 260 or 300 as the retail crowd says, and I get to buy the fear if it doesn't. That's a barbell, and I'd argue it's the more aggressive structure.

To the neutral analyst, who I expect will say the trend is intact: I agree it is. Weekly, monthly and daily SuperTrend are all up, ADX is 41.74, and the weekly TD count is only -3. That is exactly why I'm not selling everything. But a trend being intact doesn't mean the next 12 months pay off. Consider the stretch signals: RSI at 70.03, a completed daily TD-9, z-score of 1.88, %B around 0.97 and price 6.9% above the 10 EMA. The October advance came on 1.4M to 3.7M shares a day, against 20M+ in the event legs, and the MACD line is below its September 21 level even though price is higher. None of that says the trend is broken. It says the next dollar of upside is more expensive than the last.

On fundamentals, the story is good: revenue growth re-accelerated to 26%, gross margin is 84.8%, and GAAP operating income turned positive. But free cash flow margin went from 32.5% to 20.1% while revenue grew, operating cash flow fell about 7%, and cash dropped 51%. The Q4 swing to roughly +$210M of operating income came with flat sequential revenue and about $260M less operating expense, which smells like a one-time item. At about 34x forward non-GAAP earnings, 8.7x sales and a PEG of 2.2, the market has priced the optimistic reading as fact. If someone cites the StockTwits claim of 7.1x sales versus a 9.8x average, our own math says 8.7x, so I wouldn't lean on that.

Sentiment tells a similar story. Sell-side targets of 222-235, as cited second-hand, are roughly where the stock already trades, and the cited consensus of about 198.59 is below the price. The tape is full of regret posts like "sold at 86," which is classic late-rally flavor. And the same crowd is split between "gap to 260" and "back to 150."

To the conservative analyst, who will probably say get out entirely: I understand the instinct, but it throws away a strong, accelerating franchise in a confirmed multi-timeframe uptrend with ADX above 40. The stock has already gapped +29.6% and +35.3% on events this year. If you fully exit and the earnings print is another gap, you've given up the very convexity that makes this a growth name. Your concern is valid, but it should be handled with sizing, not a binary exit.

Now to what I think both of you underrate. The stock's gap behavior cuts both ways. A 35% gap down from 226.83 lands near 147, straight through the 160.05 weekly SuperTrend level. ATR of 9.24 and any stop-loss thinking understate that, so a stop is not protection here. Position size is the only real protection, which is why the plan sizes for a 35-40% gap and treats 160.05 as a re-underwrite trigger, not a hard stop. That is the disciplined way to stay in a high-volatility name.

There's also a macro overlay. Markets price "no Fed cuts in 2026" at 97%, and the FOMC meets October 28-29 with a hold at 86% and a hike still at 12%. For a long-duration, richly valued name, that removes a tailwind right as the earnings date, unconfirmed but plausibly within days, arrives.

I'll be straight about the limits. I haven't read the 10-K, the last bar may be partial, and the earnings date isn't confirmed. The plan already accounts for this: verify the live price and the filing first, and cut to a token position or zero if the Q4 opex drop was one-time or acquired revenue exceeds about 4 points of growth. Selling half into a stretched, event-prone, fully priced rally and holding bids below is the bold position, because it keeps me in the game whichever way the print goes. I'm with the trader on this one. Aggressive Analyst: Let me give up the ground I shouldn't be defending first, because I'd rather lose three weak points than the one that matters.

The conservative is right about the bids. A limit buy at 205 with the stock opening at 147 fills at 147, before anyone has read the guidance. That fill is far better than the 230 I sold at, so it isn't a loss in itself. But it puts the shares back on before I know whether 147 is cheap, and stocks that gap down on a miss often keep drifting. So pull every standing bid before the report. The ladder becomes a post-print plan, with 205-208, 195-200 and 188 as reference levels. The plan's cap of half an allocation was meant to stop bids from refilling past the target, and I blurred that in my opening.

The conservative is also right about the 212 floor. October 16 closed at 207.82, below it, so a repeat of that day leaves you holding everything into the print. The neutral's fix is better: finish by the close before the report whatever the price, and assume the date is inside ten days. I'll take that, and I'll take the point that the first tranche doesn't wait on the 10-K. Confirm the live close and go.

The neutral is right that I leaned too hard on the chart. The low end of the volume range is today's possibly partial bar, the MACD divergence is mild while the line has risen three sessions running, and the TD-9 probably completed around the 13^th with the stock up 9% since. Those are reasons not to add here, not reasons for a size. I also overstated the FCF slide. If Q4 FCF was about $474M with a margin near 27%, the weakness sits in the first three quarters, and calling it a two-year trend was too strong. It's derived and the feed disagrees by 25%, so verify it, but I'll stop leaning on it.

What holds the trim up isn't RSI. The stock is up about 52% since the August 7 close of 149.07, and our file has no new company data since then. If that gap was the Q4 print, as the timing suggests, everything since is sector re-rating and target raises. Those targets, second-hand as they are, run 222 to 235, which is minus 2% to plus 4% from today's price. The bar for the next print has risen by half while the information hasn't changed. That's why I'm not at full size.

Now the size, where I don't give ground.

To the conservative: you want a quarter or less, and zero if the date is close or the opex question is open. You're leaning on the minus 1% expected return. That's a 12-month number built on scenario weights we haven't seen, and it was my number to begin with, so let me say what it means. It says the bet is roughly fair, not that it's bad. A roughly fair bet on a business growing 26% with an 85% gross margin and every SuperTrend pointing up calls for a size you can live with, not zero. Once the only question is how much variance to carry, the neutral's loss test answers it. Half versus a quarter is a difference in pain tolerance, and analysis can't settle that.

Your zero-if-unresolved trigger has a second problem. The FY26 numbers are already in the data, so the 10-K is almost certainly filed and reading it takes an afternoon. You'd make the biggest sizing decision on a question that can be answered before the print. Answer it first, then choose between a quarter and a token.

Your plan also needs two timing calls, out before and back in after. The biggest-volume days of this recovery were gaps of roughly 30% and 35% up, whether or not they were earnings. At a quarter size you collect a quarter of the next one. You said you'd pay that price. I'd rather pay for part of it than all of it. The neutral has a fair counter, though: those gaps launched from depressed bases at 68 and 110, with low expectations. This one launches from 227 with the sell-side already at the price. That's the case for trimming. It isn't a case for going below half.

On options, a defined-risk call spread is the one idea of yours I like, since it keeps convexity with a known worst case. But I haven't seen quotes, and after two big gaps this year the event premium is probably steep. Price it, don't assume it.

To the neutral: your schedule is my plan with a deadline, which is an improvement. Your gradation of the red flags, one goes to a quarter and two go to a token, is better than the trader's either-or, so I'd adopt it. Where we differ is that I'd treat half as the ceiling, not the target. If the loss test says a third, take a third. What I won't accept is arguing the number below what someone's own tolerance allows because of an oscillator or a headline.

So I end here. Sell the first tranche today after confirming the close, the second into 230-235, and finish by the close before the report. Size from the loss test with half as the ceiling, and leave no bids through the print. Rebuild in steps afterward based on whether growth and FCF margin held, not on whether the stock is cheaper. The 160.05 level stays an alert, not a stop. It's still a Sell, and it's still the bold version, because it keeps real exposure to a third gap up while taking money off the table for the outcome that would hurt. Aggressive Analyst: We're now arguing over roughly a tenth of a standard allocation, so this is no longer a fight about direction. The things that could hurt someone are settled. The bids are gone, a calendar deadline replaces the 212 floor, the 10-K gets read today, and the first tranche goes now. Let me take what's right in your last rounds, then argue the remaining bit of size.

The neutral is right that I leaned too hard on "no new company data since August 7." Our file has no news because the feed came back empty, not because nothing happened. Barclays going from 172 to 222 and KeyCorp from 185 to 235 in a week could be informed, even though we only have them second-hand. The trim doesn't need that claim. It stands on 8.7 times sales with targets sitting on the price, and on the fact that none of the multiples we're quoting include stock comp. I'll also take the conservative's cash flow arithmetic. About $845M of free cash flow on $4.8B of revenue, against $1.04B on $3.8B a year earlier, is down about 19% on 25% growth. I walked that back too far last round.

Now the size, where I think the conservative is stacking caution.

The conservative says tolerance is a ceiling, not a target, and a roughly fair bet shouldn't use the whole budget. As a general principle I agree. But here the ceiling is already padded. Dividing the loss you'd accept by 0.45 instead of the plan's 0.37 gives about a fifth more cushion than the plan's own worst case, and that covers the drift after a gap. Then the neutral takes two-thirds of that, you take a quarter, the filing can only cut, and two flags mean zero. Each step is defensible, but together they're an exit that doesn't say so. Size should move for specific, nameable reasons: correlated software holdings like OKTA, CRWD, TWLO, NOW and ZS, or a red flag in the filing. It shouldn't move because the whole picture feels uneasy. So I'd take the full ceiling when the filing is clean and you hold nothing correlated, and drop to the neutral's two-thirds when you do. On the neutral's own example, the full ceiling is about half a standard allocation, which is the cap anyway.

On skew, I accept the up-gap is the less likely tail. A 30% gap from 227 is about 295, roughly 11 times trailing sales. But a tail isn't the whole distribution. A move to 250 or 260 is exactly what retail is already calling for. The only distribution any of us has is the trader's three scenarios, and none of us has seen the weights. Skew explains why we're not at full size, and it doesn't choose between a quarter and a third.

On the call spread, you say it gets more than a quarter of the move for a known premium. That depends on strikes and a quote nobody has seen. Pre-earnings premium is usually rich because the market is paying for the move, and it collapses after the print, so a spread only pays if the move beats what's priced in. It's a fine add-on for someone who wants more than the loss test allows, with the premium counted inside the loss budget. It isn't a substitute for shares.

On token versus zero, the neutral is right that it barely matters. I'd keep the token, because re-entering from nothing after a good print is how people chase. If both flags trip, the rebuild rules should be written before anyone sits down at the screen.

Here's what I think all three of us have underweighted. What makes or loses money isn't a quarter versus a third going into the print. It's what you do the next morning. If this gaps 35% to around 147, that's roughly 5.6 times trailing sales and low-20s forward earnings if estimates hold. That's a different stock from the one we're being asked to pay up for. If growth and free cash flow margin held, that's where the proceeds go, in thirds and with real size. If it gaps up, the question is whether guidance earns the new price, and the answer is to rebuild in steps rather than chase the open. Both branches need the rule written today. A plan with a clean exit and no re-entry rule is the fragile part of the conservative's version, more than the size of the stake.

So here's where I land. I don't know the caller's book, so this is a rule, not a number. If you're already at or below your loss-test size, don't sell, just don't add before the print. Otherwise confirm the live close, since today's 1.4M volume looks like a partial bar, and spend five minutes finding the earnings date. Sell at least half of the intended cut today, put a limit at 230 to 235 on the rest, and finish by the close before the report whatever the price. Size from the loss test at 0.45, cap it at half a standard allocation, and trim further only for correlated holdings or filing red flags. Read the 10-K today. It can cut the size but can't raise it before the print. Leave no bids resting through the event. Treat 195.85 as a stop-adding line and 160.05 as an alert, since nothing fills through a gap.

It's still a Sell, and it's still the aggressive version. The retained shares keep a real stake in a third gap up, and the cash is what has the edge when the reaction comes. Aggressive Analyst: We've converged enough that the useful thing is to say what I'm taking and where I still push.

From the conservative, I'm taking four things. First, no buying in the first session after the print, whichever way it goes. Second, a remainder scheduled by day instead of a limit plus a forced sale at the last close, compressed if the date is close, with nothing left for the FOMC afternoon on the 29^th. Third, the cluster point. OKTA, CRWD, TWLO, NOW and ZS went up together and would come down together, so TEAM gets a slice of one budget, and my two-thirds haircut for correlation was arbitrary. Fourth, the EPS arithmetic, which is the best reason to read the 10-K today.

I'd add one derived check that supports it. Net loss divided by EPS gives about 257 million diluted shares in FY26 against about 262 million in FY25. That's flat inside rounding. If it holds, buybacks have been absorbing dilution, and a good part of the $1.3B of free cash flow is the cost of standing still, not money left for owners. EPS rounding moves this by a couple of percent, so treat it as rough. Even so, I'd make it a third filing check: if buybacks ate most of the free cash flow just to hold the share count flat, that counts like the other two flags. I'd rather size off a fact in the filing than off a feeling.

From the neutral, I'm taking that a ceiling is not a target, and that his arithmetic shows what's at stake. A quarter versus a third is about a tenth of a percent of the book in either tail, so neither of us should treat it as the decision.

Where I still push is on how the haircut for soft inputs gets applied. The conservative lists them as the date, the filing, the scenario weights and stock comp. Most of those aren't soft, they're unchecked, and they can be checked this week. The date is five minutes on the investor relations page. The 10-K, stock comp, acquired revenue and the Q4 opex question are an afternoon. The scenario weights belong to the trader. A fixed haircut treats a checkable thing as permanent fog.

The guidance risk he keeps returning to isn't a soft input either. It's the event the loss test sizes for, and the 0.45 divisor already pads it for drift. You can't use it both as the thing you size for and as a reason to size below the test.

So here is a sequence I think respects all three views. The first tranche, today, takes you down to the loss-test ceiling, capped at half a standard allocation. Everyone here agrees you shouldn't be above that. The checks then decide the rest over the next few sessions, which costs nothing because the schedule runs by day.

If the date or filing is still unchecked when the schedule gets short, go to the neutral's two-thirds of the ceiling.
One flag means a quarter, and two means a token.
A clean answer on everything leaves you at the ceiling. Nothing is added, so the one-way ratchet holds.

That last bullet is where I still differ from the neutral. The softness he discounts for is what the checks remove. If you disagree, the cost of my being wrong is that tenth of a percent.

On the conservative's point that cash has the edge, I'd say it only pays if there's a rule to deploy it, and his re-entry test needs tightening. He keys it to FCF margin at or above the year-earlier quarter. On the derived numbers, the first three quarters of FY26 averaged about 18%. If the year-ago quarter is one of those, clearing it proves little, and I haven't seen that quarter's figure. Write a fixed number today from the filing, something like the roughly 27% Q4 margin holding, with growth still in the mid-20s. Pin it down before the print, because that's when the rule is cheapest to follow.

The trader's plan, as amended, is still a Sell:

Drop the 212 floor and every standing bid.
The 206 entry becomes a post-print reference level, not an order.
195.85 is a stop-adding line, and 160.05 is a re-underwrite alert, since nothing fills through a gap.
No buying in session one after the print, and rebuilding afterward happens in steps against the fixed numbers.
If you're already at or below your loss-test size, don't sell and don't add.

A few things remain unverified. The earnings date is unconfirmed, today's bar looks partial, and the Q4 figures are derived by subtraction. That's why the checks come first and the sizing follows them. The plan still keeps a real stake in a third gap up while taking money off the table for the outcome that would hurt, so I still call it the bold version. Aggressive Analyst: We're close enough now that I'd rather spend this on what I'm giving up and the places I still think the plan is wrong.

The neutral's 67.5% point lands. TEAM fell from 176.08 to 57.15, which is minus 67.5%, and sizing so that a repeat just uses up the loss limit is the same loss test with a 0.675 divisor instead of 0.45. That's a nameable reason, which was my own standard, so two-thirds of the ceiling is the default going into the print. That slide took five months and gave plenty of chances to act, so it argues for the divisor and isn't a forecast for the print. I'll take it anyway. I'll also take the correction on the size gap. Ceiling versus two-thirds is about 0.7% of the book, roughly 25 to 30 basis points in a 37% miss, not the tenth of a percent I was waving at.

On the filing, I'll take the neutral's rule that an unread 10-K counts as a flag. It's almost certainly filed and reading it is an afternoon. A default of a quarter costs nothing for anyone who does the work, and it forces the work to get done. The conservative is also right that I was backing the share count out of a rounded EPS. Minus 21 cents spans roughly 251 to 263 million shares, and with a net loss, diluted equals basic, so the RSU overhang isn't in it. Market cap over price gives about 253 million against roughly 262 million for FY25, so the count looks lower. The neutral asked for a written threshold, so here it is: fiscal year-end shares outstanding higher than a year earlier is the flag. Flat or down is not a flag. In that case buybacks absorbed dilution, which is a valuation point the trim already carries, not a sizing point.

On the date, I side with the neutral against the conservative. An unchecked date shouldn't shrink the position, because that penalizes a process gap and not a risk. If you can't find it in five minutes, assume it's inside the window. Last year's volume spike was October 30 and 31, so finish selling by the close on the 28^th and leave nothing for the FOMC afternoon. That fixes the timing risk without cutting the stake.

Now the two places I still push. The first is the re-entry rule. We all agree nothing gets bought in the first session after the print, and I've signed on to that. But the rule as drafted is a four-way AND, and it fails in exactly the case where the proceeds have the best odds. Say TEAM gaps down hard, reported growth and free cash flow margin hold, and the guide steps down a couple of points. A binary rule says buy nothing, and a trim quietly becomes an exit that nobody chose. So grade it. If everything passes, buy the full schedule over the following week, starting in session two. If reported growth and cash flow pass but the guide is soft, run a half-size schedule. If reported growth slips below the low 20s, or free cash flow margin misses without a credible explanation, buy nothing. Since the guide is the swing factor, someone should also pull how this company's guides have compared with what it actually delivered. Our file doesn't have that. If it habitually guides low, a guide a few points under reported growth means less than it looks like.

The second push is the rebuild target. I'm accepting two-thirds going in because it pays for not knowing the print: unseen scenario weights, the skew, an unconfirmed date. After the print those are known, and the next one is a quarter away. So I'd let a rebuild that passes the tests go to the full ceiling, never above half a standard allocation. If the neutral thinks the 67.5% reasoning makes two-thirds permanent, fine, but write that number down today. The rebuild target should be set before the screen is red or green.

I'd also push back on the conservative's closing line about sizing so the print can't hurt. Nothing at this size makes it unable to hurt. A 37% miss on a third of a standard allocation still costs real money. The aim is that the loss is survivable, so you can act with a clear head the next morning instead of being forced to. That's where this plan's edge comes from.

So here's where I land. It's still a Sell, and the trader's half of a standard allocation becomes the cap, not the target. Take the most you'd accept losing on TEAM from one print, divide by 0.45, hold two-thirds of that, and put OKTA, CRWD, TWLO, NOW and ZS inside the same budget. If you're already at or below that size, don't sell and don't add. Otherwise sell at least half the cut today and work the rest by day. Pull a slice forward on any move to 230 or better, and finish by the close before the report, or by the 28^th if the date is unknown. Leave no standing bids. Read the 10-K today for three flags: a one-time Q4 opex drop, acquired revenue above about four points of growth, and net dilution. One flag or an unread filing takes you to a quarter, and two flags take you to a token. Treat 195.85 as a stop-adding line and 160.05 as a re-underwrite alert. Buy nothing in session one, then rebuild on the graded rule. That keeps a real stake for a third gap up and keeps the cash to act on the reaction.

Conservative Analyst¶

Conservative Analyst: The aggressive analyst has just spent several hundred words defending the trader's plan and calling it the bold version. So the real question isn't whether to sell. It's whether the plan as written reduces risk, and in four places I think it quietly puts risk back.

The first is the resting bids. The plan trims to half an allocation, then rests bids at 205-208, 195-200 and 188. The aggressive analyst calls that buying the fear. But the risk the plan itself names is a 35-40% gap, and a gap doesn't walk down through your bids, it opens below all of them. A limit buy fills at the open if the open is under the limit. So if the print is bad and the stock opens near 147, every bid fills at once, at the worst prices of the first print. You go from half an allocation back to a full one, immediately after the event you were worried about. If bids make sense, they go in after the reaction is known.

The second is the sell floor. The plan scales out into strength and says not to sell below about 212. The earnings date is unconfirmed but plausibly days away, and a price floor makes the de-risking depend on the stock cooperating. On October 16 this stock went from 217 to 207.82 in one session. A slightly deeper version of that day and the plan is still holding everything into the print. Risk reduction should be tied to the calendar, not a price. If the date is unknown, assume it's inside the window, because that's the cheaper mistake.

The third is the stop. The plan lists 160.05 and then admits it won't fill through a gap. The aggressive analyst agrees. Entry at 206 to 160 is a 22% loss, but 206 to roughly 147 is closer to 28%. The re-underwrite trigger is a weekly close below 160, so it fires after the damage is done. I agree sizing is the only protection, so follow that through. A 35% gap is about 8.5 ATRs. No standard allocation was sized for that. Half an allocation still loses about 18% of a full one in a 37% miss, and the stock then needs +59% to recover. I don't know the caller's book, so the test is simple: if that loss on one print is more than they'd accept, the position is too big.

The fourth is the plan's own math. An expected return near -1% with a fat left tail means we're being paid nothing for the risk. Half size gives the same tail, just smaller. The trend is a reason not to go to zero, but it describes what has happened, not what the print pays. I'd go to a quarter of an allocation or less before the report, and to zero if the date lands inside the next week or the Q4 opex question is unresolved. Re-entry after the print costs us a possible gap up, and I'd pay that.

On convexity, owning shares is linear with a hole in it. If someone wants gap-up participation, a defined-risk call spread or a collar at least makes the worst case a known number. I haven't seen options pricing, and it's probably expensive going into earnings, but the loss is capped.

On fundamentals, I'd sharpen the aggressive analyst's point. The FCF margin slide from 32.5% to 20.1% runs over two years, through 27.1% in FY25, so it's a trend, not one bad year. Add cash down 51%, a 0.78 current ratio, equity down 21%, and about $2.6B of investing and financing outflows against $1.35B of operating cash flow. The plan treats the 10-K as a check before executing, but the burden runs the other way. Selling doesn't need the filing, holding does. Don't delay the trim waiting for it, and use the filing to decide whether to come back.

On macro, a hold is 86% priced, so it gives no upside. The risk is in the tails: a 12% hike chance and only 24% odds of no dissent. The sentiment report also suggests this is a sector-wide rally (OKTA, CRWD, TWLO, NOW, ZS) and beta is 1.23, so a sector unwind could land on top of the print. I wouldn't lean much on the sentiment data, though. It's 30 messages with 3 tagged, and the regret posts are colour, not evidence.

To the neutral analyst, who I expect will say the trend is intact: I agree. All three SuperTrends are up and ADX is 41.74. But ADX going from 10 to 42 in 15 sessions tells us how fast the move was, not how durable it is. The daily SuperTrend at 195.85 is nearly 16% below price, and trailing-stop logic assumes continuous trading that an earnings gap skips. A weekly TD count of -3 says the trend isn't exhausted, but the print doesn't care about the count. The technical report also says the levels at 212, 204, 199.84 and 195.85 are indicator-derived, not validated support. You can be right about the trend and still take a 35% hit overnight.

So I support the Sell, but I'd make it deeper than the plan, time-based instead of price-based, and without bids resting through the event. Conservative Analyst: I think we've converged on most of the mechanics, so let me say what I'm taking from each of you and where I still push.

I'm taking four things. The aggressive analyst pulled the standing bids, and I'm glad. I'll accept the neutral's point that a gap fill isn't automatically the worst price, since the real problem was buying before we know the guidance. You're both right that the 10-K is almost certainly out and should be read today, so my "zero if the opex question is unresolved" trigger was too blunt. And the neutral's graded response to red flags is better than an on/off switch. I'd also drop the macro as a reason for size. A hold at 86% isn't news, and the chart items I leaned on are really about how to manage the shares we keep.

Now the disagreements.

First, the aggressive analyst's line that half versus a quarter is just pain tolerance. Tolerance sets a ceiling, and it doesn't tell you to sit at the ceiling. You take risk up to your limit when you're paid for it. Your own number says the 12-month expected return is about -1%, and you've told us the bar has risen by half since August 7 on no new company information. If that's true, there's no reason to use the whole risk budget. The analysis does say something here: stay well under the cap.

Second, the neutral's loss test divides by 0.37, which treats the gap as the whole loss. The aggressive analyst said himself a few minutes ago that stocks that gap down on a miss often keep drifting. January and February are in our own file, with 8 and 14 million share days on the way from the 170s to the 50s. And if the post-August advance simply reverses, you land near 149, which is about -34%. So 0.37 is a plausible bad case, not a tail. I'd divide by 0.45 or 0.5. On the neutral's example, that takes a 1% loss limit from a 2.7% position to roughly 2 to 2.2%.

Third, the claim that sizing scales both tails equally. It scales the magnitudes, not the odds. The neutral's own figures show it: at a quarter allocation, the miss costs about 9% of a full position while a 30% gap up adds 7.5%. And the aggressive analyst conceded that the 30% and 35% gaps launched from bases of 68 and 110 with low expectations. From 227, a 30% gap means about 295, or roughly 11 times sales, with targets already at 222 to 235. The up-gap is the less likely tail and the down-gap the more likely one, so equal scaling flatters the upside.

Fourth, the cash flow rebuttal. The neutral says Q4 free cash flow snapped back. On the report's derived numbers, Q4 was about $474M on $1,766M of revenue, roughly 27%, against about 27% in Q4 a year earlier. That's flat year on year, not a recovery. The first three quarters then come to roughly $845M of free cash flow on $4.8B of revenue, against about $1.04B on $3.8B the year before. That's free cash flow down about 19% while revenue rose about 25%. One quarter matching last year, derived by subtraction from a feed that disagrees with the SEC figure by 25%, doesn't undo three weak ones. I'll give the neutral the buyback timing, though. If the March-quarter equity drop was repurchases, they were bought cheap. But it also means there's no net cash cushion at 147 and no obvious buyer of last resort.

Fifth, the filing. The aggressive analyst says to answer the opex question before the print, and I agree. But a clean 10-K only tells us the base is sound. It doesn't tell us what guidance will say or how a stock at 8.7 times sales reacts. So the filing should only be able to move size down, never up past what the loss test allows.

Sixth, the aggressive analyst's point that I need two timing calls and he doesn't. His plan finishes the trim before the report and rebuilds in steps afterward, so he has the same two calls. The difference is how much is exposed in between.

On convexity, this is where I'd answer the "you give up the gap up" objection. If someone wants real participation in a third gap up, a small defined-risk call spread gets more than a quarter of the move for a premium known today, without carrying a 37% downside on the shares. I haven't seen quotes, and after two 30% gaps the premium is probably rich, so price it against the history of gaps before using it. But it's a better answer to convexity than holding extra shares.

On execution, the earnings date should be a five-minute check on the investor relations page, so someone should do that rather than plan around not knowing. And a calendar deadline means the sale should be front-loaded. If the first of three even tranches is a third and the report lands in three days, we're still mostly there. Sell at least half of the intended cut now, work the rest into 230 to 235, and finish by the close before the report.

So my position is this. Confirm the live close and sell the first and largest tranche today. Target about a quarter of a standard allocation, and go to a third only if the loss test with the wider divisor and a clean filing both allow it. If one red flag trips, go to a token position. If both trip, go to zero, because a token isn't meaningfully different at that point. Leave no bids resting through the print. After the print, rebuild in steps on whether growth and free cash flow margin held, not on whether the stock is cheaper. I'm not arguing against owning a franchise this good. I'm arguing against owning more of it than a roughly fair bet with a left-skewed event deserves. Conservative Analyst: I'll start with what I'm giving up, because some of my last round doesn't hold. The neutral is right that the drop to about 149 is already inside 0.37, so it can't justify the 0.45 divisor. The justification is drift after the gap, and our file shows it: 176 in November to 57 in April, with 8 and 14 million share days on the way down. That makes 0.45 a middle estimate, not a pessimistic one. I also repeated the line that the bar has risen on no new company information, and an empty news feed isn't an empty quarter. The trim stands on 8.7 times sales with targets sitting at the price. I'll take a token over zero, as long as it's written down that holding it is no reason to add before the print. And you're both right that a call spread's premium is a loss and belongs inside the loss budget. It's an extra for someone who wants more than the test allows, not a substitute for being smaller.

Now the neutral's charge that my logic proves too much. If a roughly zero expected return meant zero shares, I'd be at zero. What keeps a quarter is that I might be wrong about the trend and about my own read of the print, and I want a seat to be wrong from. That's judgment, not derivation. But two-thirds of the ceiling is judgment too. Neither of us is computing it. The real question is which way to lean when every input to the loss test is soft: the 0.45, the date, the scenario weights none of us has seen, and a multiple that excludes stock comp. When the inputs are soft, you hold less than the ceiling they give you, not all of it.

That's also why the aggressive's rule bothers me. He says the filing can cut the size but can't raise it before the print, then says to take the full ceiling when the filing is clean. Those only fit together if the full ceiling is the default, and that's the default I'm disputing. A clean 10-K tells you the base is sound. It doesn't tell you what guidance will say or how a stock at 8.7 times sales reacts.

He also says size should move only for nameable reasons. Mine are nameable. Free cash flow is down about 19% over three quarters on 25% revenue growth, which all three of us now accept. The date is unconfirmed. The skew is left-heavy. And there's an unresolved quality-of-earnings question under the valuation. The 34x forward multiple sits on $6.74 of EPS, while the last four quarters of GAAP EPS were minus 21 cents. Even if I annualize Q4's derived 53 cents, the number we don't trust, GAAP comes to about $2.10. On my arithmetic that means roughly two-thirds of the earnings the multiple is built on is adjustments we haven't seen itemized, and on the GAAP-ish figure the stock is north of 100 times. The 10-K may answer that, and that's the best reason to read it today.

On correlation, the aggressive's version is the weakest part of his rule. Dropping from the full ceiling to two-thirds if you hold OKTA, CRWD, TWLO, NOW and ZS treats five names that tripled together as slightly more exposure than one. In a sector unwind they're one position. The loss limit should apply to the cluster, so TEAM gets a share of one ceiling, not two-thirds of its own.

I agree with his point about the morning after. Both branches need rules written today. But his own numbers are generous. Low-20s forward earnings at 147 assumes estimates survive a miss that's big enough to cause a 35% gap, and those estimates exclude stock comp. And "deploy in thirds with real size" the next morning repeats the resting-bid mistake we already fixed, which is buying before the guidance is digested. I'd write the rule so there's no buying in the first session. The first tranche goes in only after the call and the filing are read, and only if growth is still around the mid-20s and free cash flow margin is back at or above the year-earlier quarter.

He also said the cash is what has the edge when the reaction comes. If so, more cash means more edge, and that argues for a smaller retained stake, not a larger one. Shares help in a gap up and cash helps in a gap down. We've agreed the gap up is the less likely tail and starts from a stock already priced at its targets.

On execution, I'd tighten one thing. A limit at 230 to 235 on the second piece, then a forced sale at the last close, puts a big slice on the single worst day to be a seller. I'd schedule the remainder by day across the sessions left, and use any move to 230 or better to pull a slice forward. That keeps the plan on a calendar instead of a price, which is what we agreed it should be.

So I land here. If you're already at or below your loss-test size, don't sell and don't add. Otherwise confirm the live close, find the earnings date, and sell the first and largest piece today. Target a quarter of a standard allocation. I'd go to the neutral's third only if three things hold: the loss test at 0.45 allows it, the filing is clean with stock comp understood, and nothing correlated sits in the book. One red flag means a quarter, two means a token, and no bids rest through the print. Treat 195.85 as stop adding and 160.05 as an alert. I'm not arguing against owning a franchise this good. I'm arguing that when the bet is roughly fair, the inputs are soft, and the print is skewed against us, the right size is the smaller one. Conservative Analyst: I'll start with what I'm dropping, because the neutral landed some fair hits. The gap between $6.74 and roughly two dollars of GAAP-ish EPS was just as true at 110 and at 149. It says the stock is expensive, but it says nothing about how much event risk to carry for the next week, so it belongs in the filing check and not in the sizing. "Cash has the edge" also proves too much, since followed through it ends at zero shares, and I've said I'd keep a seat. You're also right that I was layering: the wider divisor, then below the cap, then the ratchet, then a quarter. That counts the same cushion several times. So I'll collapse it. Take the ceiling from the loss test at 0.45, hold two-thirds of it, never exceed half a standard allocation, and put the whole software cluster inside one budget. That's your number, and on a 4-5% standard allocation it's about a third. I won't fight over 15 basis points.

I'm also taking two fixes from the aggressive. The earnings date is five minutes on the investor relations page, so it's a to-do that sets the schedule, not a reason to size down. And a fixed re-entry bar beats the year-ago quarter. The next report is the September quarter, whose comparison is one of the weak FY26 quarters. The first three averaged about 18%, though I haven't seen the split, so clearing that proves little. Write down the roughly 27% Q4 margin instead. I'd add one thing: key it to guided growth as well as reported growth. This stock gaps on guidance, and a mid-20s reported quarter with a stepped-down guide is exactly the print that gaps down on good-looking numbers.

Now to where I still push, mostly on the aggressive.

First, a clean filing shouldn't lift you to the full ceiling. You say the checks remove the softness. They remove some of it, but they test whether the base is sound, and thresholds like four points of acquired revenue are lines we drew in this conversation. Passing three screens of our own design doesn't tell you what guidance says or how 8.7 times sales reacts to it, and no afternoon with the 10-K resolves that. A clean filing should leave you at the default and a flag should take you down. If clean takes you up, the ratchet is two-way with a different name.

Second, the double-counting charge. The ceiling answers how much I can lose and survive. Where I sit below it answers how much I'm paid to risk. The trader's own figure is about minus one percent, and none of us has seen the weights behind it, so "roughly fair" is a best estimate, not a finding. You can't call a bet fair on unseen weights and then use that to justify the full budget.

Third, your tenth-of-a-percent argument cuts both ways. If I'm wrong by being small, I give up a tenth of a percent of upside, and if you're wrong by being big, you lose a tenth of a percent. By the neutral's numbers the extra slice costs about 15 basis points in a miss and pays about 12 in a pop, and we agreed the pop is the thinner tail. When the errors cost about the same and the skew is against you, take the smaller error.

On the share count, it's a good check but a rough one. EPS rounds to the cent, so minus 21 cents spans roughly 251 to 263 million shares before you even count rounding in the net loss. That range covers flat, down and up. Market cap over price gives about 253 million, a few percent below the roughly 262 million implied for FY25. That suggests the count has shrunk, so buybacks did more than stand still. Also, with a net loss, diluted equals basic, so the unvested RSU overhang isn't in that count at all. I'd count it as a flag, but read repurchase dollars against stock comp off the cash flow statement instead of backing it out of EPS.

Fourth, anything still unchecked when the schedule runs short should count as a flag, not as a move to two-thirds. If it's unchecked then, either nobody did the work or the data isn't there, and you shouldn't size up on that.

So here's where I land. If you're already at or below your loss-test size, don't sell and don't add. If you're flat, don't buy. Otherwise confirm the live close, find the date, and sell at least half the cut today. Large-cap tech reports this week and could move software multiples before TEAM's own date, so there's no reason to wait. Work the rest by day, pull a slice forward on any move to 230 or better, and leave no bids resting through the print. The default is two-thirds of the ceiling, cluster-adjusted and capped at half a standard allocation. One flag takes you to a quarter, and two or more take you to a token. Unchecked counts as a flag, and a clean filing leaves you at the default. After the print, buy nothing in session one. Then rebuild in tranches only against the numbers written down today: Q4-level free cash flow margin, reported growth in the mid-20s, guided growth within a couple of points of that, and the opex question answered. Treat 195.85 as a stop-adding line and 160.05 as a re-underwrite alert.

I'm not arguing against owning a franchise this good. I'm arguing for sizing it so the print can't hurt, and for making the buying decisions after we know what the print said. Conservative Analyst: We're close enough that I'll just say where I'm moving and where I'm not.

On the date, the neutral is right. An unfound date is a process gap, not a risk, so I'll stop counting it as a flag. If five minutes on the investor relations page doesn't turn it up, assume it's inside the window and compress the schedule. The close on the 28^th is a good backstop because it also keeps the FOMC decision on the 29^th out of the position. If the real date is earlier, the earlier date wins. An unread filing stays a flag, and I'm glad the aggressive took that. I'll also take his share-count threshold: year-end shares higher than a year earlier is a flag, and flat or down isn't. Read the number off the 10-K cover page, because market cap over price and a rounded EPS are both proxies. And his correction of my wording is fair. Nothing at this size makes the print unable to hurt. The real standard is that it can't hurt enough to dictate what you do the next morning.

Now the two places I still disagree. The first is the rebuild target. The aggressive says two-thirds going in pays for not knowing the print, and since those unknowns resolve, a passing rebuild can go to the full ceiling. That doesn't fit with what he just accepted. He took the neutral's 67.5% reasoning, and that reasoning has nothing to do with the print. It's about what this stock did to holders over five months, and the file shows 8 and 14 million share days on the way down. That risk is still there the morning after, whichever way the print goes. So two-thirds is the working size, not an event discount.

I'd allow one exception, and it should hang on price, not the calendar. If every test passes and the stock is below the 206 the trader already picked as a rebuild level, you're being paid more than you are today, and going to the ceiling is defensible. If it gaps up and passes every test, you're paying 10 to 11 times sales, and the answer is to rebuild toward two-thirds and stop. Size should follow what you're paid, not what you know. That replaces a layer instead of adding one. Write the 206 line down today so nobody picks it at the screen.

The second is the soft guide. I accept grading the re-entry, and a half schedule is better than an all-or-nothing rule that turns a trim into an exit nobody chose. But define half as half the distance between what you hold and the target, in tranches, and only if the price is at or below that rebuild line. A soft guide on a stock that just gapped up is exactly where good-looking numbers fade, and I'd buy nothing there.

I'd also pull the guidance history, but be careful what it proves. If they habitually guide low, the street knows it too, and consensus already sits above the guide. A guide a few points under reported growth can be normal for them and still be a miss against what's priced in. The history tells you about the business over the next few quarters, not how the stock reacts to this guide.

One housekeeping point on the free cash flow bar. The roughly 27% Q4 margin is derived by subtraction, from a dataset where the feed is off by about 25% on annual FCF. Take the bar from the 10-K's own cash flow statement, because you'll be stuck with whatever number you write down today.

Here's where I land. It's still a Sell. Take the most you'd accept losing on TEAM from one print, divide by 0.45, hold two-thirds of that, cap it at half a standard allocation, and put OKTA, CRWD, TWLO, NOW and ZS inside the same budget. If you're already at or below that size, don't sell and don't add. If you're flat, don't buy.

Otherwise, confirm the live close, since 1.43 million shares looks like a partial bar. Sell at least half the cut today and spread the rest by day. Pull a slice forward on any move to 230 or better, and finish by the close before the report, or by the 28^th if the date is unknown. Leave no standing bids, and sell high-cost lots first if taxes matter.

Read the 10-K today. The flags are a one-time Q4 opex drop, acquired revenue above about four points of growth, and net dilution. One flag or an unread filing takes you to a quarter, and two take you to a token. A clean filing leaves you at two-thirds, not above it. Treat 195.85 as a stop-adding line and 160.05 as a re-underwrite alert, since nothing fills through a gap.

After the print, buy nothing in session one. Then rebuild in tranches only against numbers written down today: growth still in the mid-20s, guided growth within a couple of points of that, free cash flow margin near the filing's Q4 level or credibly explained, and a clean answer on the opex swing. Go above two-thirds only below the 206 line.

I'm not arguing against owning a franchise this good. I'm arguing for owning it at a size where the print gets to inform the next decision and not force it.

Neutral Analyst¶

Neutral Analyst: You two are closer than the tone suggests. One of you wants roughly half a standard allocation into the print, the other a quarter or less, and both want to be smaller than where the trader started. So I won't argue about whether to trim. I'll argue about how, because that's where each of you slips.

Aggressive first. Calling the plan a barbell doesn't fix the mechanics the conservative flagged. If the print is the event we're worried about, bids at 205, 195 and 188 don't let you buy fear. They hand back much of the trim at the open, before you've read the guidance. The 212 sell floor has the same problem: the plan sells when the stock cooperates and holds when it doesn't. October 16, 217 to 207.82 in one session, is exactly the day you'd want to have already sold. I'd push back on the conservative's claim that a gap fill is automatically the worst price, though. After a bad print the open is sometimes the low and sometimes not. The issue is sequencing, because you shouldn't be adding before you know the news.

The aggressive technical case is also thinner than it sounded. The 1.4 million share low end of the October volume range is today's bar, which the technical report says may be partial. The MACD divergence is labelled mild and unconfirmed, and the line has risen three sessions running. The daily TD nine probably completed around October 13, and the stock is up about 9% since. Z-scores are under 2, and the weekly and monthly readings are healthy. The macro overlay is a stretch too. "No cuts in 2026" at 97% with about ten weeks of 2026 left is close to saying the Fed holds in October and December, and hike odds fell from around 30% to 12% this week. That's not a tailwind, but it isn't a new headwind either. I'd use the chart to decide how to treat the shares we keep, not how many to keep.

Now the conservative. A quarter or less, and zero if the date is close, leans hard on that minus 1% expected return. It comes from three scenarios with weights we haven't seen, and a few points of probability would move it to plus 2 or minus 4. What it really says is that we aren't paid for variance. That argues for sizing to what we can tolerate, not for the smallest number. Sizing scales both tails equally. At a quarter allocation the 37% miss costs about 9% of a full position, but a 30% gap up like May or August only adds about 7.5%. The stock has had heavy-volume event days in both directions this year, including the 8 to 14 million share days in the January and February selloff.

I also think the fundamentals case is overstated. On the report's derived numbers, Q4 free cash flow was about $474M, up roughly 28% year on year, at a margin near 27%, about where Q4 was a year earlier. That puts the margin weakness in the first three quarters, and the exit rate looks much better than the 20.1% full-year figure. It's derived by subtraction and the feed disagrees with the SEC data on FCF, so verify it, but it's hard to call a steady two-year slide when the last quarter snapped back. Cash falling by half mostly reflects what management chose to do with it. Cash roughly equals debt, and a current ratio under one is normal when deferred revenue sits in current liabilities. If the March-quarter equity drop was buybacks, they were done when the stock was a fraction of today's price. The real fundamental unknowns are stock comp and that Q4 opex swing. The 35 to 43 times FCF and 34 times forward earnings both sit before stock comp, and the GAAP operating margin for the year was 0.2%.

On "selling doesn't need the filing, holding does": the FY26 numbers are already in the data, so the 10-K is almost certainly out, and reading it takes an afternoon, not weeks. Do it in parallel with the first sale, not instead of it. On options, I'd price a collar or call spread, but after two roughly 30% gaps this year the event premium is probably steep. A collar also gives away the upside the aggressive analyst wants to keep. I'd treat options as an alternative for someone who wants to hold more than the loss test below allows, not as the default.

Here's what I'd do. Take the loss you'd accept on this one name from a single print, divide by 0.37, and that's your maximum position. If 1% of your portfolio is the pain limit, that's about 2.7% of the portfolio. I suspect for many books that lands around a third to 40% of a standard allocation, between your numbers, but let the test decide, not an average.

For the schedule, sell the first piece now, after confirming the live close since today's bar may be partial. Sell the next piece into any strength toward 230 to 235. Finish by the close before the report whatever the price. The date isn't confirmed, so assume it's inside about ten days. The October 30 and 31 volume spike last year is consistent with the report landing right about now.

I wouldn't leave any bids resting through the print. The proceeds are your dry powder, so deploy them after the reaction, in tranches, using 205 to 208, 195 to 200 and 188 as reference levels rather than standing orders. If you're flat, don't initiate before the print. For ordinary non-gap drift, I'd treat the daily SuperTrend at 195.85 as a "stop adding, take another notch off" line. The weekly 160.05 stays a re-underwrite alert, not a stop, since nothing fills through a gap.

The filing questions are whether the Q4 opex drop was one-time, how much revenue was acquired, what stock comp is, and why free cash flow was weak early in the year. If one red flag trips, I'd go to about a quarter. If both trip, go to a token position, not automatically zero, because neither touches the 26% growth or the 85% gross margin.

After the print, if the reaction is strong and guidance supports it, rebuild toward half in steps rather than chasing. If it gaps down, the question is whether growth and FCF margin held, not whether it's cheaper than yesterday.

So my adjusted view is still a reduction, but to a size set by the loss test, on a calendar instead of a price floor, with the buying after the print instead of before. That keeps a real stake in a trend every timeframe confirms, and it keeps the worst outcome survivable. Neutral Analyst: We're now arguing about 25% versus 35% of a standard allocation. That gap is smaller than the uncertainty in what anyone's standard allocation means. The mechanics are settled: no standing bids, a calendar deadline instead of a price floor, an early first tranche, and the filing read in parallel. I'll go through where each of you is still stretching, then say where I land.

To the aggressive analyst: you said you won't accept arguing below someone's tolerance because of an oscillator or a headline. The conservative has dropped the oscillators and the macro. His case now rests on expected return, the cash flow pattern and the skew of the print, so that's a different argument. Your own reason for trimming also leans on "no new company data since August 7, so everything since is sector re-rating." Our file has no company data because the news feed came back empty, not because nothing happened. Targets rose by $30 to $50 in a week, and some of that may be informed. The trim doesn't need that claim. At 8.7 times sales with targets sitting on the price, it stands on its own. Hold the claim loosely, and note that both of you have been repeating it.

To the conservative: your logic proves too much. If an expected return near zero means don't spend the risk budget, smaller is always better and the argument ends at zero. You stop at a quarter, so something else is setting the number, and that something is keeping a stake in a trend every timeframe confirms. That's the same reason the aggressive gives for a larger number. The minus 1% is also a 12-month figure from three scenarios whose weights we haven't seen. It tells us the bet isn't obviously cheap. It doesn't tell us how to size the next two weeks. You've also stacked conservative choices: a wider divisor, then well under the cap, then a filing that can only cut, then zero if two flags trip. Each is defensible alone. Together they land on a position too small to matter either way, which amounts to an exit made without saying so.

On the balance sheet, cash roughly equals debt and the company makes about $1.3B of free cash flow a year. That's not a missing cushion. The unpriced issue is stock comp. GAAP operating income of $10M against $1.35B of operating cash flow means a lot of non-cash expense. If the buybacks mostly offset dilution, free cash flow overstates what is left for owners. That argues for caution on the multiple, but it isn't a liquidity problem.

Now the concessions. You're right about the cash flow. I said Q4 snapped back, and it didn't. The margin was about 27% against about 27% a year earlier, while the first three quarters were down roughly 19% in dollars on 25% revenue growth. FY25 was flat across its quarters, so there's no seasonal excuse. That's a real change, and Q4 only got margin back to last year's level. It's why the cash flow statement matters more than the headline growth number. I'll also accept your 0.45 divisor. It costs little, 2.2% of the book instead of 2.7% on a 1% loss limit, and a risk limit should hold when nobody is at the screen. The reason is drift after the gap, though. The reversal back to about 149 is already inside 0.37.

I also accept that the up-gap and down-gap odds aren't symmetric. A 30% gap from 227 is about 295, roughly 11 times trailing sales. But a move to 250 or 260 isn't exotic, and the skew explains why we're trimming from full size. It doesn't explain why a quarter beats a third.

On token versus zero, that's the least important disagreement here. A position under about 10% of a standard allocation changes nothing either way. I'd keep a token, because both flags together still leave a 26% grower with 85% gross margins, and re-entering from zero after a good print is when people chase. Pick the one you'll actually follow.

On options, I agree you should price a call spread. Remember the sold strike caps the gap-up you're buying it for, and after two 30% gaps you're probably paying for a big move before you know it's more than priced. The premium is the loss. It doesn't get around the loss test.

So here's where I land. Take the most you'd accept losing on this one name from a single print and divide by 0.45. That's the ceiling. Hold about two-thirds of it, and never more than half of a standard allocation. With a 1% loss limit that's a 2.2% ceiling and roughly a 1.5% position. For a standard allocation of four to five percent of the book, that's about a third. If you hold other software names that have run the same way, such as OKTA, CRWD, TWLO, NOW and ZS, count them together, since a sector unwind would hit them on the same day. If you're already at or below that size, don't sell. Just don't add before the print, and don't buy if you're flat.

For execution, spend five minutes on the investor relations page for the date. Confirm the live close, since today's volume of 1.43M suggests a partial bar. Sell at least half of the intended cut now, put a limit at 230 to 235 on the rest, and finish by the close before the report whatever the price. If you hold taxable gains, sell the highest-cost lots first. Leave no bids resting through the print.

Read the 10-K today, and I'll take the conservative's one-way ratchet on it. A bad answer moves you toward a quarter or a token, and a clean one leaves you at target. Nobody adds on a clean filing before the print. After the report, rebuild in steps on whether growth and free cash flow margin held, not on whether the price is lower. The daily SuperTrend at 195.85 is a "stop adding" line, and 160.05 stays an alert, since nothing fills through a gap.

That is still a Sell, to about a third of a standard allocation, sized by a loss test and run on a calendar. It keeps a real stake in the trend and keeps the bad print survivable. Neutral Analyst: We've narrowed this to a quarter, a third or a half of a standard allocation, so I'll say what I'm taking from each of you and then where I still push.

From the conservative I'm taking three things. First, no buying in the first session after the print, whichever way it goes. "Deploy in thirds the next morning" brings back the mistake we fixed by pulling the bids. Second, scheduling the remainder by day instead of a limit plus a forced sale at the last close. Just compress it if the date turns out to be only a few sessions away, and don't leave the last slice for the FOMC afternoon on the 29^th. Third, the cluster point. Five software names that tripled together are one bet in a sector unwind, so a flat haircut to two-thirds for correlated holdings is arbitrary. If you own them, TEAM gets a slice of one budget.

Your EPS arithmetic is also the best reason to read the 10-K today. I'd add that the +35% gap on August 7 very probably was the Q4 print, which is the quarter with the unexplained opex swing. That's inference, but if the swing was one-time, the last leg of this rally rests partly on a number that won't repeat. That is why the ratchet should only cut size.

From the aggressive I'm taking that the plan needs a re-entry rule written today. After the print, nothing goes on in session one. Then buy in tranches over several sessions, only if growth is still around the mid-20s, the Q4 opex question has a clean answer, and free cash flow margin is at or above the year-earlier quarter. We haven't seen that quarter's number, so look it up now.

Now the pushback. Conservative, your case has drifted from sizing to valuation. The gap between $6.74 and roughly $2 of GAAP-ish EPS is real, and I'd want stock comp itemized. But it was just as true at 110 and at 149. It says the stock is expensive, which the trim already reflects. It says nothing about how much event risk to carry for two weeks. The cash-has-the-edge argument also proves too much. Followed through, it ends at zero shares, and you've said you'd keep a seat.

Let me also put numbers on this. On a four to five percent standard allocation, a quarter versus a third differs by about 0.4% of the book. Times a 37% miss, that's about 15 basis points. Times a 30% pop, it's about 12. We're arguing over roughly a tenth of a percent of the portfolio in either tail. Your soft-inputs point is legitimate, and that's why I'm at two-thirds of the ceiling instead of the ceiling. That is the margin for soft inputs. Divisor, then below the cap, then a ratchet, then a quarter is the same margin counted three times.

Aggressive, the full-ceiling default is where I disagree most. The ceiling is the most you can lose in a bad case you chose. It isn't a target when the bet is roughly fair. You say a clean filing earns the full ceiling, but a clean 10-K tells you the base is sound and tells you nothing about guidance at 8.7 times sales. Your "nameable reasons" standard also cuts against you, because soft inputs are nameable: an unconfirmed date, scenario weights nobody has seen, and a multiple that excludes stock comp. Your morning-after math has the same issue. Low-20s forward earnings at 147 holds only if estimates survive a miss big enough to cause that gap. And be careful about treating the call spread as the answer to convexity. The premium is a loss and it counts inside the budget.

Here's where I land. Take the most you'd accept losing on this name from one print and divide by 0.45. That's the ceiling. Hold about two-thirds of it, never more than half a standard allocation, and apply it to the whole software cluster if you own the others. If you're already at or below that size, don't sell, and don't add before the print. If you're flat, don't buy.

If you need to cut, spend five minutes finding the earnings date, since last year's volume spike was October 30 and 31. Confirm the live close, because today's volume looks like a partial bar. Sell at least half the cut now. Spread the rest across the sessions before the report, and pull a slice forward on any move to 230 or better. Leave no bids resting through the print. Sell high-cost lots first if taxes matter.

Read the 10-K today. One red flag, either a one-time Q4 opex drop or acquired revenue above about four points of growth, moves you to a quarter. Two flags move you to a token, and I'd keep the token to avoid chasing later. A clean filing leaves you at target, not above it. Treat 195.85 as a "stop adding" line and 160.05 as a re-underwrite alert, since nothing fills through a gap.

It's still a Sell, but sized by a loss test, run on a calendar, and with all the buying after the news. Neutral Analyst: We're down to the last few inches, so I'll say what I'm taking, where each of you is still stretching, and where I land.

From the conservative, I'm taking the guided-growth condition on re-entry. A mid-20s reported quarter with a stepped-down guide is exactly the print that gaps down on good-looking numbers. From the aggressive, I'm taking that most of our "soft inputs" are just unchecked, and the date and filing can be nailed down before the schedule gets short. I'd also pin the rebuild bar to the roughly 27% Q4 free cash flow margin, but as a band rather than a hair trigger. One quarter's cash flow is noisy, so "mid-20s or better, or a clear timing explanation" does the job of stopping you from rationalizing at the screen.

Aggressive, your "tenth of a percent" fits quarter versus third. It doesn't fit your actual proposal, which is the full ceiling on a clean filing. On a 1% loss limit and a 4-5% standard allocation, the ceiling is about 2.2% of the book, near half a standard allocation. Two-thirds of it is about 1.5%. That's a gap of roughly 0.7% of the book, or about 25 to 30 basis points in a 37% miss, around twice the quarter-versus-third gap. It's still small, but it's the weakest-supported part of your plan. A clean 10-K tells you the base is sound and nothing about guidance at 8.7 times sales.

You also say two-thirds double counts the padding already in the 0.45 divisor. It doesn't, and the reason is concrete. The 0.45 is a plausible bad case, not a worst case. At the ceiling, a 45% fall uses your whole loss limit, and anything worse breaches it. At two-thirds, the fall that exhausts the limit is about 67.5%. That's the drawdown this stock already delivered from 176.08 in November to 57.15 in April, and it's in our own file. I'm not forecasting a repeat. I'm saying to hold the size at which a repeat of what this stock has already done to its holders just uses up the limit. That's a nameable reason, and it passes your own test.

Conservative, you've adopted two-thirds, so we're close. I'd split your "unchecked counts as a flag" rule. I'll give you the filing. The trader's own rule says a one-time Q4 opex drop should cut the position hard, the multiple depends on that number, and an unread filing is the same unknown, so one flag is a fair default. I won't give you the date. If you can't find it, assume it's inside the window and compress the schedule. That's a timing fix, and shrinking the position for it penalizes a process gap rather than a risk.

Your "equal errors, skewed odds, so take the smaller error" argument also has the same problem as "cash has the edge." Applied consistently, it works at every size and ends at zero. The two-thirds anchor is a better stopping point because it has a reason attached. The marginal slice between a quarter and a third is also worth close to nothing in expectation. The trader's -1% is a twelve-month figure on weights none of us has seen, and multiplied by a slice of about 0.4% of the book it's under a basis point. Past that it's variance preference, which the loss test already sets.

On the buyback check, I'd read repurchases against stock comp in the cash flow statement, as you said. Market cap over price gives about 253M shares against roughly 262M weighted in FY25, so the count appears to have fallen a few percent. I'd only treat this as a flag if the filing shows net dilution, and we should write the threshold down now so it doesn't become a vibe.

So here is where I land. It's still a Sell, sized by a rule, not a number I can hand you. Take the most you'd accept losing on this name from one print and divide by 0.45. Hold two-thirds of that, never more than half a standard allocation, and count OKTA, CRWD, TWLO, NOW and ZS in the same budget. With a 1% limit and a 4-5% standard weight, that works out to about a third of a standard allocation. If you're already at or below that size, don't sell and don't add. If you're flat, don't buy.

Otherwise, find the earnings date, confirm the live close since today's 1.43M volume looks partial, and sell at least half the cut today. Spread the rest across the sessions before the report, pull a slice forward on any move to 230 or better, and finish by the close before the report. Don't leave the last slice for the FOMC afternoon on the 29^th. Leave no standing bids, and sell high-cost lots first if taxes matter.

Read the 10-K today. A one-time Q4 opex drop or acquired revenue above about four points of growth is a flag. One flag, or an unread filing, takes you to a quarter. Two flags take you to a token. A clean filing leaves you at two-thirds, not above it.

The 206 entry becomes a post-print reference level, not an order. 195.85 is a stop-adding line, and 160.05 is a re-underwrite alert, since nothing fills through a gap. After the print, buy nothing in the first session. Then add in tranches only if reported growth is still mid-20s, guided growth is within a couple of points of that, free cash flow margin is back near the mid-20s or credibly explained, and the opex question has a clean answer.

That keeps a real stake in a trend every timeframe confirms, caps the damage at a size you chose in advance, and puts the buying after the news instead of before it. Neutral Analyst: I think we're down to one real disagreement and a few wording fixes.

The real one is whether a passing print earns a bigger position than the one you carry into it. Conservative, you're right, and I'll put it in my own terms because the two-thirds was my argument. I justified it with the slide from 176 to 57, which describes how this stock behaves, not what the report says. The print resolves only a narrow set of things: the date, the guide, and the flags in the filing. It doesn't resolve a daily ATR around 4%, a sector that moves as one block, or an FOMC decision the same week. It also doesn't settle the scenario weights behind the minus 1%, which is a twelve-month view that one quarter doesn't change. Aggressive, most of what you want to treat as paid for by the haircut isn't removed by the print. So two-thirds of the ceiling is the working size, and the ceiling is a limit, not a rebuild target. The next point to revisit it is the next quarter's information.

Conservative, I don't like your exception, though, because it fails on its own logic. You said size should follow what you're paid, and I agree. But a fixed price of 206 doesn't measure what you're paid once the print resets estimates, and a guide always does. Today's 226.83 on forward EPS of 6.74 is about 33.7x. Suppose the print cuts estimates 10%, so EPS goes to about 6.07, and the stock gaps to 206. That is about 33.9x, the same multiple as today on slower growth, and your rule says go to the ceiling. Now suppose estimates rise 10% to about 7.41 and the stock goes to 250. That is also about 33.7x on faster growth, and your rule says stop. The line gets the sign wrong in the cases it exists for. It is also a price trigger set before the information arrives, which is what we all objected to about the 212 floor.

So I'd replace it, not add to it. Go above two-thirds only if the post-print forward multiple, on post-print estimates, is below today's roughly 34x, and reported growth, guide, cash flow and the opex answer all pass. That is the same number of layers as yours, but it moves with the estimates. Forward EPS excludes stock comp, so it's good for comparing against today and not much else. A clean print that gaps down also means the market saw something our checklist missed, so even when the gate opens, the buying goes in tranches starting in session two.

On the soft guide, grading beats a four-way AND, Aggressive, and I'll take it. Conservative's definition of half is cleaner: half the distance between what you hold and the target, in tranches, behind the same multiple gate. It matters less than it sounds, though. With a clean filing you're already at working size, so a soft guide means you do nothing under either version. The graded schedule only bites for someone a flag cut to a quarter or a token who then gets a decent print. That is the person it protects, since otherwise a trim turns into an exit nobody chose.

On guidance history, Conservative is right that it won't tell you how the stock reacts, because the Street knows the habit. It does tell you how wide the band should be. If they usually guide three or four points under what they deliver, "within a couple of points" is the wrong band, and you want to learn that today, not at the screen. So pull the history, set the band from it, and write it down.

On the cash flow bar, I agree with Conservative that it should come from the 10-K's own cash flow statement, not from my subtraction. I'd write the revenue bar as a dollar figure too. Mid-20s growth on the year-ago September quarter of about $1,433M is roughly $1.79B, derived from the same dataset, so confirm it against the filing.

Two last challenges. Aggressive, the cash only has an edge up to the ceiling, and the ceiling is already about half a standard allocation. Most of the proceeds sit in cash through the quarter whatever happens, so don't plan around deploying them. Conservative, your standard that the print shouldn't dictate the next morning is already met at loss-test size, and going smaller is the layering you gave up last round.

We also now have enough conditions that I'd worry whether anyone follows them with the stock moving 10% in a session. The core fits on a card: a size from the loss test, a calendar deadline, three filing flags, nothing bought in session one, and bars written down before the print.

So here is where I land. It's still a Sell, sized by a rule and not a number I can hand you. Take the most you'd accept losing on this name from one print and divide by 0.45. Hold two-thirds of that, never more than half a standard allocation, and count OKTA, CRWD, TWLO, NOW and ZS inside the same budget. If you're at or below that size, don't sell and don't add. If you're flat, don't buy.

Otherwise, confirm the live close, since 1.43M shares looks like a partial bar, and find the earnings date. Sell at least half the cut today and work the rest by day, pulling a slice forward on any move to 230 or better. Finish by the close before the report, or by the 28^th if you can't find the date. Leave no standing bids, and sell high-cost lots first if taxes matter.

Read the 10-K today for three flags: a one-time Q4 opex drop, acquired revenue above about four points of growth, and net dilution in year-end shares. One flag or an unread filing takes you to a quarter, and two flags take you to a token. A clean filing leaves you at two-thirds. Treat 195.85 as a stop-adding line and 160.05 as a re-underwrite alert, since nothing fills through a gap. The 206 level is a reference, not a trigger.

After the print, buy nothing in session one. Then rebuild in tranches only against the numbers written down today, and go above two-thirds only if the post-print forward multiple is below roughly 34x with everything else passing. That keeps a real stake in a trend every timeframe confirms, and it keeps the loss survivable. It also puts the buying after the news and ties it to what you're paying then, not to a price chosen today.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Underweight TEAM: reduce the position but keep a stake. Size the stake with a loss test: take the most you would accept losing from one print, divide by 0.45, and hold two-thirds of that. Never hold more than 50% of a standard allocation (SA), and count OKTA/CRWD/TWLO/NOW/ZS inside the same budget; with a 1% loss limit and a 4-5% SA this is roughly one-third of SA. Confirm the live close first (today's 1.43M-share bar may be partial), then sell at least half of the cut today, work the rest by day (pulling a slice forward on any move to $230+), and finish by the close before the report, or by Oct 28 if the date cannot be found. Leave no resting bids through the print, and if flat do not buy before it; $195.85 is a stop-adding line and a weekly close below $160.05 is a re-underwrite alert, not a stop, because nothing fills through a 35-40% gap.

Investment Thesis: DECISION. The Research Manager (Underweight), the trader (a Sell that maps to a partial trim) and all three risk analysts end in the same place: reduce, do not exit. That rules out Hold, because the evidence is not balanced on price. It also rules out Sell, because the franchise and the multi-timeframe trend argue for keeping exposure. FY26 revenue was $6.57B (+26%, H2 +29.6%), gross margin is about 85%, GAAP operating income turned positive, and weekly, monthly and daily SuperTrend are all up with ADX at 41.74.

WHY REDUCE. (1) Valuation already pays for a clean print. The stock trades at about 8.7x sales, about 34x forward non-GAAP EPS of $6.74, and about 43x SEC-based FCF (a 2.3% yield), and all of these multiples exclude stock-based compensation (SBC). TTM GAAP EPS is -$0.21. Sell-side targets of $222-235 sit on the price, and the cited consensus of $198.59 is 12% below it. (2) The payoff is skewed to the left. Using the bull's own payoffs (clean +13%, middle -15%, miss -37%), the 12-month expected return is about -1%. (3) The conservative analyst's cash-flow arithmetic held up and was conceded by both other analysts. FCF over the first nine months of FY26 was about $845M on $4.8B of revenue, against about $1.04B on $3.8B a year earlier, roughly -19% on +25% revenue. The derived Q4 margin of about 27% only matched the prior year's level, and FY25 showed no seasonality. (4) The Q4 GAAP operating income of about +$210M came from roughly $260M less opex on flat sequential revenue, which is unexplained. The +35% gap on Aug 7 was probably that print, and the stock is up 52% since. (5) The daily chart is stretched: RSI 70.03, a completed TD-9, z-score 1.88, %B about 0.97, price 6.9% above the 10 EMA, and light October volume. The earnings date is unconfirmed, beta is 1.23, the move is a sector-wide rally, and the FOMC meets Oct 28-29.

HOW THE DEBATE AMENDED THE TRADER'S PLAN. (a) Resting bids at 205-208, 195-200 and 188 are removed before the print. The conservative analyst showed that a gap opens below all of them, so every bid would fill at once before anyone had read the guidance. Those levels become post-print reference levels, and the 206 entry is a reference, not an order. (b) The 'don't trim below ~212' floor is replaced by a calendar deadline. Oct 16 closed at 207.82, which would have left the full position in place going into the print. © Size comes from the neutral analyst's loss test, not a fixed 50%. The 0.45 divisor allows for drift after a gap. Holding two-thirds of the resulting ceiling means it would take a 67.5% fall to use up the whole loss limit, which is the size of this stock's own 176.08-to-57.15 slide. Correlated software names share one budget. (d) Read the 10-K today and check three flags: a one-time Q4 opex drop, acquired revenue above about 4 points of growth, and year-end shares outstanding higher than a year earlier (net dilution). One flag, or an unread filing, cuts the position to about 25% of SA; two flags cut it to a token. A clean filing leaves the position at two-thirds of the ceiling, not above it, because the filing can only reduce size before the print.

POST-PRINT RULES, written down now. Buy nothing in the first session after the print. From session two onward, rebuild in tranches only if all of the following hold: revenue of about $1.79B or more (mid-20s growth on $1,433M; confirm against the filing); guided growth within a band set from the company's own guidance history; FCF margin near the 10-K's actual Q4 level or credibly explained; and a clean answer on the opex question. If reported results pass but the guide is soft, close half the gap to target, in tranches. Go above two-thirds of the ceiling only if the post-print forward P/E on updated estimates is below today's roughly 34x. This uses the neutral analyst's estimate-adjusted gate rather than a fixed $206 trigger, which would get the direction wrong once estimates reset. Never go above 50% of SA. Two consecutive quarters with Rule of 40 below 46 count as a thesis break.

WHAT WOULD CHANGE THE CALL. Toward Hold or Overweight: a clean 10-K (recurring opex, modest acquired revenue, flat or falling share count) plus a print that passes the rebuild rules with the forward multiple at or below 34x. Toward Sell: two filing flags, Rule of 40 below 46, growth below 24%, or a weekly close below $160.05.

PRICE TARGET: $224 over 12 months. Method: probability-weighting the plan's scenario valuation. Clean case 226.83 x 1.13 = $256.3, middle case x 0.85 = $192.8, miss case x 0.63 = $142.9. The 60% clean weight is the bull's figure; the 25/15 split between middle and miss is my assumption, since those weights were not shown. That gives 0.60x256.3 + 0.25x192.8 + 0.15x142.9 = $223.4, consistent with the plan's stated ~-1% (226.83 x 0.99 = $224.6), rounded to $224. Cross-checks: the target sits inside the $222-235 sell-side cluster and above the $198.59 consensus. 26x NTM FCF ($226-236) is reached only in the clean case. A target slightly below the current price alongside a fat left tail is exactly why this is Underweight rather than Sell.

DATA GAPS that lower confidence: the 10-K is unread; SBC, NRR and cRPO are missing; the earnings date is unconfirmed; the last bar may be partial; Q4 figures are derived by subtraction; feed FCF ($1,655M) disagrees with the SEC-based figure ($1,319M); and there is no options chain.

Current Price: 226.83

Price Target: 224.0

Confidence: Medium

Time Horizon: 12 months (execute the trim over the next 1-2 weeks, before the Q1 FY27 print; reassess after the print)

Trading Analysis Report: TEAM¶

I. Analyst Team Reports¶

Market Analyst¶

TEAM: Technical Analysis Report (as of 2026-10-21)¶

1. Data-integrity notes¶

2. Indicators chosen and why¶

3. Price context (252 sessions, 2025-10-21 to 2026-10-21)¶

4. Trend structure¶

5. Momentum¶

6. Volatility and risk geometry¶

7. Volume (OBV)¶

8. Exhaustion and stretch¶

9. Synthesis¶

10. Summary table¶

Sentiment Analyst¶

News Analyst¶

TEAM (Atlassian Corporation): News and Macro Report, week of 2026-10-14 to 2026-10-21¶

1. Data coverage¶

2. Macro: what the prediction markets say¶

3. Global market and sector headlines (headline-level only)¶

4. Implications for TEAM¶

5. Gaps to fill¶

6. Summary table¶

Fundamentals Analyst¶

TEAM (Atlassian Corporation): Fundamental Research Report¶

1. Snapshot and market data¶

2. Income statement¶

Annual history (USD millions)¶

Quarterly trend (USD millions; * = derived as FY total minus Q1–Q3)¶

3. Cash flow¶

Annual (USD millions)¶

4. Balance sheet¶

5. Insider transactions¶

Co-founder selling (the dominant flow)¶

Officers (periodic, vest-linked)¶

Directors¶

6. Data-quality flags¶

7. Takeaways for traders¶

8. Summary table¶

II. Research Team Decision¶

Bull Researcher¶

1. Growth is accelerating at scale¶

2. Profitability is turning¶

3. The bear's best fundamental point has an answer¶

4. The AI narrative cuts in TEAM's favor so far¶

5. Technicals show a trend, not a blow-off¶

6. Sell-side and macro are still catching up¶

Where the bear has a point¶

Why I'm still constructive¶

What I concede¶

1. The exit rate changes your own hurdle math¶

2. The Rule of 40 is flat only on the annual number¶

3. The Q4 swing: the outlier is Q3¶

4. The exit rate on revenue is not soft¶

5. The balance sheet shows redeployment, not burn¶

6. AI: use a non-lagging indicator¶

7. Technicals¶

8. Your "change my mind" list¶

Where I land¶

What you got right¶

What still stands¶

1. Your own M&A assumption leaves the acceleration mostly intact¶

2. In the full-bull case, the valuation gap is one to four turns of multiple¶

3. The odds math needs a hedge, and we both said that¶

Your question: name a print outcome short of a collapse that makes me sell¶

Where I land¶

1. Your question: sell the starter at $250, or does the range move?¶

2. What I'm changing¶

3. What I still hold¶

a) Your table is a "value today" snapshot, and a holder lives on a different clock¶

b) The pre-print starter is a coin flip, and I'll size it that way¶

c) Waiting has a price¶

d) What nobody here can resolve¶

4. Final plan¶

Bottom line¶

The short answer¶

What you've earned¶

Where the math doesn't hold¶

1. The 28x line is a trigger, not a ceiling¶

2. The $200 rung's +12% assumes a fill that is anti-correlated with the good outcome¶

4. Implications for `TEAM`¶